| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | RNA polymerase II transcription regulatory region sequence-specific DNA binding | ZNF132 ZNF17 ZNF134 ZNF19 ZSCAN5B ZNF776 ZNF671 MYBBP1A ZFP90 ZNF773 USF3 ZNF547 ZNF143 ZIK1 ZNF211 ZNF35 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 TAF1L ZNF548 ZNF441 ZNF286A ZNF551 ZNF345 ZNF304 | 4.03e-37 | 1459 | 76 | 49 | GO:0000977 |
| GeneOntologyMolecularFunction | DNA-binding transcription factor activity, RNA polymerase II-specific | ZNF132 ZNF17 ZNF134 ZNF19 ZSCAN5B ZNF776 ZFP90 ZNF773 USF3 ZNF547 ZNF143 ZIK1 ZNF211 ZNF35 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF333 ZNF418 ZNF417 ZNF623 ZNF548 ZNF441 ZNF286A ZNF551 ZNF345 ZNF304 | 1.94e-32 | 1412 | 76 | 45 | GO:0000981 |
| GeneOntologyMolecularFunction | RNA polymerase II cis-regulatory region sequence-specific DNA binding | ZNF132 ZNF17 ZNF134 ZSCAN5B ZNF776 ZNF671 MYBBP1A ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 ZNF548 ZNF286A ZNF551 ZNF345 ZNF304 | 3.54e-32 | 1244 | 76 | 43 | GO:0000978 |
| GeneOntologyMolecularFunction | cis-regulatory region sequence-specific DNA binding | ZNF132 ZNF17 ZNF134 ZSCAN5B ZNF776 ZNF671 MYBBP1A ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 ZNF548 ZNF286A ZNF551 ZNF345 ZNF304 | 8.64e-32 | 1271 | 76 | 43 | GO:0000987 |
| GeneOntologyMolecularFunction | TAP complex binding | 2.07e-13 | 9 | 76 | 6 | GO:0062061 | |
| GeneOntologyMolecularFunction | CD8 receptor binding | 2.07e-13 | 9 | 76 | 6 | GO:0042610 | |
| GeneOntologyMolecularFunction | TAP1 binding | 5.16e-13 | 10 | 76 | 6 | GO:0046978 | |
| GeneOntologyMolecularFunction | TAP2 binding | 5.16e-13 | 10 | 76 | 6 | GO:0046979 | |
| GeneOntologyMolecularFunction | TAP binding | 5.16e-13 | 10 | 76 | 6 | GO:0046977 | |
| GeneOntologyMolecularFunction | beta-2-microglobulin binding | 2.26e-12 | 12 | 76 | 6 | GO:0030881 | |
| GeneOntologyMolecularFunction | natural killer cell lectin-like receptor binding | 2.98e-11 | 17 | 76 | 6 | GO:0046703 | |
| GeneOntologyMolecularFunction | T cell receptor binding | 9.23e-11 | 20 | 76 | 6 | GO:0042608 | |
| GeneOntologyMolecularFunction | MHC class I protein binding | 2.08e-09 | 32 | 76 | 6 | GO:0042288 | |
| GeneOntologyMolecularFunction | 14-3-3 protein binding | 1.17e-08 | 42 | 76 | 6 | GO:0071889 | |
| GeneOntologyMolecularFunction | peptide antigen binding | 3.05e-08 | 49 | 76 | 6 | GO:0042605 | |
| GeneOntologyMolecularFunction | MHC protein binding | 8.60e-08 | 58 | 76 | 6 | GO:0042287 | |
| GeneOntologyMolecularFunction | protein-folding chaperone binding | 3.43e-05 | 161 | 76 | 6 | GO:0051087 | |
| GeneOntologyMolecularFunction | 6-phosphofructo-2-kinase activity | 8.54e-05 | 4 | 76 | 2 | GO:0003873 | |
| GeneOntologyMolecularFunction | antigen binding | 8.63e-05 | 190 | 76 | 6 | GO:0003823 | |
| GeneOntologyMolecularFunction | fructose-2,6-bisphosphate 2-phosphatase activity | 1.42e-04 | 5 | 76 | 2 | GO:0004331 | |
| GeneOntologyMolecularFunction | DNA-binding transcription activator activity, RNA polymerase II-specific | USF3 ZNF143 ZNF268 ZNF175 ZNF300 ZNF225 ZNF227 ZNF112 ZNF345 | 2.70e-04 | 560 | 76 | 9 | GO:0001228 |
| GeneOntologyMolecularFunction | DNA-binding transcription activator activity | USF3 ZNF143 ZNF268 ZNF175 ZNF300 ZNF225 ZNF227 ZNF112 ZNF345 | 2.92e-04 | 566 | 76 | 9 | GO:0001216 |
| GeneOntologyMolecularFunction | phosphofructokinase activity | 2.97e-04 | 7 | 76 | 2 | GO:0008443 | |
| GeneOntologyMolecularFunction | sugar-phosphatase activity | 6.31e-04 | 10 | 76 | 2 | GO:0050308 | |
| GeneOntologyMolecularFunction | carbohydrate phosphatase activity | 7.69e-04 | 11 | 76 | 2 | GO:0019203 | |
| GeneOntologyMolecularFunction | peptide binding | 1.34e-03 | 318 | 76 | 6 | GO:0042277 | |
| GeneOntologyMolecularFunction | protein dimerization activity | GPD1L SUPT3H USF3 HLA-A HLA-B HLA-E HLA-F HLA-G HLA-H HIP1R ZNF397 TAF1L | 1.90e-03 | 1205 | 76 | 12 | GO:0046983 |
| GeneOntologyMolecularFunction | carbohydrate kinase activity | 2.86e-03 | 21 | 76 | 2 | GO:0019200 | |
| GeneOntologyMolecularFunction | protein homodimerization activity | 3.71e-03 | 815 | 76 | 9 | GO:0042803 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent | 5.25e-14 | 8 | 75 | 6 | GO:0002485 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent | 1.47e-11 | 16 | 75 | 6 | GO:0002486 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway | 2.26e-11 | 17 | 75 | 6 | GO:0002484 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class Ib | 2.26e-11 | 17 | 75 | 6 | GO:0002476 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of peptide antigen via MHC class Ib | 3.38e-11 | 18 | 75 | 6 | GO:0002428 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous peptide antigen via MHC class I | 3.38e-11 | 18 | 75 | 6 | GO:0042590 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class I | 1.81e-10 | 23 | 75 | 6 | GO:0019885 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen | 3.16e-10 | 25 | 75 | 6 | GO:0002483 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation via MHC class Ib | 3.16e-10 | 25 | 75 | 6 | GO:0002475 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous antigen | 1.58e-09 | 32 | 75 | 6 | GO:0019883 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of peptide antigen via MHC class I | 7.66e-09 | 41 | 75 | 6 | GO:0002474 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell mediated cytotoxicity | 8.91e-09 | 42 | 75 | 6 | GO:0001916 | |
| GeneOntologyBiologicalProcess | protection from natural killer cell mediated cytotoxicity | 2.00e-08 | 9 | 75 | 4 | GO:0042270 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous peptide antigen | 2.05e-08 | 48 | 75 | 6 | GO:0002478 | |
| GeneOntologyBiologicalProcess | regulation of T cell mediated cytotoxicity | 3.78e-08 | 53 | 75 | 6 | GO:0001914 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous antigen | 6.57e-08 | 58 | 75 | 6 | GO:0019884 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class Ib via ER pathway | 1.84e-07 | 4 | 75 | 3 | GO:0002488 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class Ib via ER pathway, TAP-dependent | 1.84e-07 | 4 | 75 | 3 | GO:0002489 | |
| GeneOntologyBiologicalProcess | T cell mediated cytotoxicity | 2.06e-07 | 70 | 75 | 6 | GO:0001913 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell mediated immunity | 2.87e-07 | 74 | 75 | 6 | GO:0002711 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 3.31e-07 | 40 | 75 | 5 | GO:0045953 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of peptide antigen | 3.37e-07 | 76 | 75 | 6 | GO:0048002 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 3.76e-07 | 41 | 75 | 5 | GO:0002716 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte mediated cytotoxicity | 4.25e-07 | 79 | 75 | 6 | GO:0001912 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent | 4.59e-07 | 5 | 75 | 3 | GO:0002481 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous peptide antigen via MHC class Ib | 4.59e-07 | 5 | 75 | 3 | GO:0002477 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 7.56e-07 | 47 | 75 | 5 | GO:0001911 | |
| GeneOntologyBiologicalProcess | positive regulation of cell killing | 8.07e-07 | 88 | 75 | 6 | GO:0031343 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 1.26e-06 | 52 | 75 | 5 | GO:0031342 | |
| GeneOntologyBiologicalProcess | negative regulation of neuron projection development | 2.72e-06 | 169 | 75 | 7 | GO:0010977 | |
| GeneOntologyBiologicalProcess | regulation of T cell mediated immunity | 3.16e-06 | 111 | 75 | 6 | GO:0002709 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte mediated cytotoxicity | 6.00e-06 | 124 | 75 | 6 | GO:0001910 | |
| GeneOntologyBiologicalProcess | positive regulation of natural killer cell cytokine production | 7.46e-06 | 11 | 75 | 3 | GO:0002729 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 8.39e-06 | 76 | 75 | 5 | GO:0042269 | |
| GeneOntologyBiologicalProcess | natural killer cell cytokine production | 9.92e-06 | 12 | 75 | 3 | GO:0002370 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell cytokine production | 9.92e-06 | 12 | 75 | 3 | GO:0002727 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 1.08e-05 | 80 | 75 | 5 | GO:0002715 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation | 1.16e-05 | 139 | 75 | 6 | GO:0019882 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 1.29e-05 | 83 | 75 | 5 | GO:0002707 | |
| GeneOntologyBiologicalProcess | regulation of cell killing | 1.59e-05 | 147 | 75 | 6 | GO:0031341 | |
| GeneOntologyBiologicalProcess | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1.78e-05 | 150 | 75 | 6 | GO:0002824 | |
| GeneOntologyBiologicalProcess | positive regulation of lymphocyte mediated immunity | 1.78e-05 | 150 | 75 | 6 | GO:0002708 | |
| GeneOntologyBiologicalProcess | negative regulation of cell projection organization | 2.22e-05 | 233 | 75 | 7 | GO:0031345 | |
| GeneOntologyBiologicalProcess | positive regulation of adaptive immune response | 2.48e-05 | 159 | 75 | 6 | GO:0002821 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated immunity | 2.62e-05 | 96 | 75 | 5 | GO:0002704 | |
| GeneOntologyBiologicalProcess | T cell mediated immunity | 2.85e-05 | 163 | 75 | 6 | GO:0002456 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity | 4.04e-05 | 105 | 75 | 5 | GO:0042267 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte mediated immunity | 4.25e-05 | 175 | 75 | 6 | GO:0002705 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immunity | 4.83e-05 | 109 | 75 | 5 | GO:0002228 | |
| GeneOntologyBiologicalProcess | negative regulation of innate immune response | 5.99e-05 | 114 | 75 | 5 | GO:0045824 | |
| GeneOntologyBiologicalProcess | leukocyte mediated cytotoxicity | 6.14e-05 | 187 | 75 | 6 | GO:0001909 | |
| GeneOntologyBiologicalProcess | positive regulation of CD8-positive, alpha-beta T cell proliferation | 1.30e-04 | 5 | 75 | 2 | GO:2000566 | |
| GeneOntologyBiologicalProcess | fructose 2,6-bisphosphate metabolic process | 1.94e-04 | 6 | 75 | 2 | GO:0006003 | |
| GeneOntologyBiologicalProcess | regulation of lymphocyte mediated immunity | 2.00e-04 | 232 | 75 | 6 | GO:0002706 | |
| GeneOntologyBiologicalProcess | regulation of transcription by RNA polymerase III | 2.12e-04 | 32 | 75 | 3 | GO:0006359 | |
| GeneOntologyBiologicalProcess | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 2.14e-04 | 235 | 75 | 6 | GO:0002822 | |
| GeneOntologyBiologicalProcess | negative regulation of response to biotic stimulus | 2.25e-04 | 151 | 75 | 5 | GO:0002832 | |
| GeneOntologyBiologicalProcess | tolerance induction | 2.78e-04 | 35 | 75 | 3 | GO:0002507 | |
| GeneOntologyBiologicalProcess | regulation of adaptive immune response | 3.12e-04 | 252 | 75 | 6 | GO:0002819 | |
| GeneOntologyBiologicalProcess | inner ear development | 3.19e-04 | 253 | 75 | 6 | GO:0048839 | |
| GeneOntologyBiologicalProcess | negative regulation of immune effector process | 3.48e-04 | 166 | 75 | 5 | GO:0002698 | |
| GeneOntologyBiologicalProcess | positive regulation of natural killer cell mediated cytotoxicity | 4.14e-04 | 40 | 75 | 3 | GO:0045954 | |
| GeneOntologyBiologicalProcess | positive regulation of cytokine production involved in immune response | 4.67e-04 | 99 | 75 | 4 | GO:0002720 | |
| GeneOntologyBiologicalProcess | positive regulation of type II interferon production | 5.43e-04 | 103 | 75 | 4 | GO:0032729 | |
| GeneOntologyBiologicalProcess | positive regulation of natural killer cell mediated immunity | 5.49e-04 | 44 | 75 | 3 | GO:0002717 | |
| GeneOntologyBiologicalProcess | positive regulation of CD8-positive, alpha-beta T cell activation | 5.76e-04 | 10 | 75 | 2 | GO:2001187 | |
| GeneOntologyBiologicalProcess | regulation of CD8-positive, alpha-beta T cell proliferation | 5.76e-04 | 10 | 75 | 2 | GO:2000564 | |
| GeneOntologyBiologicalProcess | ear development | 5.98e-04 | 285 | 75 | 6 | GO:0043583 | |
| GeneOntologyBiologicalProcess | CD8-positive, alpha-beta T cell proliferation | 7.02e-04 | 11 | 75 | 2 | GO:0035740 | |
| GeneOntologyBiologicalProcess | cell killing | 8.81e-04 | 307 | 75 | 6 | GO:0001906 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte mediated immunity | 9.11e-04 | 309 | 75 | 6 | GO:0002703 | |
| GeneOntologyBiologicalProcess | positive regulation of immune effector process | 1.04e-03 | 317 | 75 | 6 | GO:0002699 | |
| GeneOntologyBiologicalProcess | platelet-derived growth factor receptor-beta signaling pathway | 1.33e-03 | 15 | 75 | 2 | GO:0035791 | |
| GeneOntologyBiologicalProcess | regulation of T cell tolerance induction | 1.33e-03 | 15 | 75 | 2 | GO:0002664 | |
| GeneOntologyBiologicalProcess | fructose metabolic process | 1.51e-03 | 16 | 75 | 2 | GO:0006000 | |
| GeneOntologyBiologicalProcess | regulation of dendritic cell differentiation | 1.51e-03 | 16 | 75 | 2 | GO:2001198 | |
| GeneOntologyBiologicalProcess | transcription by RNA polymerase III | 1.57e-03 | 63 | 75 | 3 | GO:0006383 | |
| GeneOntologyBiologicalProcess | T cell tolerance induction | 1.71e-03 | 17 | 75 | 2 | GO:0002517 | |
| GeneOntologyBiologicalProcess | positive regulation of nitric oxide biosynthetic process | 1.72e-03 | 65 | 75 | 3 | GO:0045429 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response | 1.79e-03 | 239 | 75 | 5 | GO:0050777 | |
| GeneOntologyBiologicalProcess | positive regulation of nitric oxide metabolic process | 1.87e-03 | 67 | 75 | 3 | GO:1904407 | |
| GeneOntologyBiologicalProcess | regulation of cytokine production involved in immune response | 1.93e-03 | 145 | 75 | 4 | GO:0002718 | |
| GeneOntologyBiologicalProcess | female pregnancy | 2.14e-03 | 249 | 75 | 5 | GO:0007565 | |
| GeneOntologyBiologicalProcess | multicellular organism growth | 2.14e-03 | 249 | 75 | 5 | GO:0035264 | |
| GeneOntologyBiologicalProcess | detection of bacterium | 2.38e-03 | 20 | 75 | 2 | GO:0016045 | |
| GeneOntologyBiologicalProcess | positive regulation of transcription by RNA polymerase III | 2.38e-03 | 20 | 75 | 2 | GO:0045945 | |
| GeneOntologyBiologicalProcess | regulation of type II interferon production | 2.46e-03 | 155 | 75 | 4 | GO:0032649 | |
| GeneOntologyBiologicalProcess | positive regulation of production of molecular mediator of immune response | 2.64e-03 | 158 | 75 | 4 | GO:0002702 | |
| GeneOntologyBiologicalProcess | regulation of CD8-positive, alpha-beta T cell activation | 2.87e-03 | 22 | 75 | 2 | GO:2001185 | |
| GeneOntologyBiologicalProcess | detection of other organism | 3.14e-03 | 23 | 75 | 2 | GO:0098543 | |
| GeneOntologyBiologicalProcess | regulation of tolerance induction | 3.14e-03 | 23 | 75 | 2 | GO:0002643 | |
| GeneOntologyBiologicalProcess | cytokine production involved in immune response | 3.29e-03 | 168 | 75 | 4 | GO:0002367 | |
| GeneOntologyBiologicalProcess | type II interferon production | 3.36e-03 | 169 | 75 | 4 | GO:0032609 | |
| GeneOntologyBiologicalProcess | defense response to bacterium | 3.56e-03 | 405 | 75 | 6 | GO:0042742 | |
| GeneOntologyBiologicalProcess | carbohydrate phosphorylation | 3.71e-03 | 25 | 75 | 2 | GO:0046835 | |
| GeneOntologyCellularComponent | MHC class Ib protein complex | 1.12e-14 | 7 | 74 | 6 | GO:0032398 | |
| GeneOntologyCellularComponent | MHC class I protein complex | 3.32e-13 | 10 | 74 | 6 | GO:0042612 | |
| GeneOntologyCellularComponent | MHC class I peptide loading complex | 4.70e-12 | 14 | 74 | 6 | GO:0042824 | |
| GeneOntologyCellularComponent | cis-Golgi network membrane | 1.92e-11 | 17 | 74 | 6 | GO:0033106 | |
| GeneOntologyCellularComponent | Golgi medial cisterna | 1.54e-10 | 23 | 74 | 6 | GO:0005797 | |
| GeneOntologyCellularComponent | MHC protein complex | 3.48e-10 | 26 | 74 | 6 | GO:0042611 | |
| GeneOntologyCellularComponent | lumenal side of endoplasmic reticulum membrane | 2.39e-09 | 35 | 74 | 6 | GO:0098553 | |
| GeneOntologyCellularComponent | endoplasmic reticulum exit site | 7.59e-09 | 42 | 74 | 6 | GO:0070971 | |
| GeneOntologyCellularComponent | lumenal side of membrane | 1.75e-08 | 48 | 74 | 6 | GO:0098576 | |
| GeneOntologyCellularComponent | ER to Golgi transport vesicle membrane | 1.02e-07 | 64 | 74 | 6 | GO:0012507 | |
| GeneOntologyCellularComponent | phagocytic vesicle membrane | 4.87e-07 | 83 | 74 | 6 | GO:0030670 | |
| GeneOntologyCellularComponent | cis-Golgi network | 5.61e-07 | 85 | 74 | 6 | GO:0005801 | |
| GeneOntologyCellularComponent | COPII-coated ER to Golgi transport vesicle | 2.56e-06 | 110 | 74 | 6 | GO:0030134 | |
| GeneOntologyCellularComponent | recycling endosome membrane | 2.85e-06 | 112 | 74 | 6 | GO:0055038 | |
| GeneOntologyCellularComponent | endoplasmic reticulum protein-containing complex | 5.38e-06 | 125 | 74 | 6 | GO:0140534 | |
| GeneOntologyCellularComponent | Golgi cisterna | 8.38e-06 | 135 | 74 | 6 | GO:0031985 | |
| GeneOntologyCellularComponent | coated vesicle membrane | 1.11e-05 | 215 | 74 | 7 | GO:0030662 | |
| GeneOntologyCellularComponent | phagocytic vesicle | 1.98e-05 | 157 | 74 | 6 | GO:0045335 | |
| GeneOntologyCellularComponent | Golgi stack | 3.21e-05 | 171 | 74 | 6 | GO:0005795 | |
| GeneOntologyCellularComponent | transport vesicle membrane | 7.98e-05 | 293 | 74 | 7 | GO:0030658 | |
| GeneOntologyCellularComponent | early endosome membrane | 1.06e-04 | 212 | 74 | 6 | GO:0031901 | |
| GeneOntologyCellularComponent | endocytic vesicle membrane | 1.06e-04 | 212 | 74 | 6 | GO:0030666 | |
| GeneOntologyCellularComponent | recycling endosome | 1.36e-04 | 222 | 74 | 6 | GO:0055037 | |
| GeneOntologyCellularComponent | coated vesicle | 2.83e-04 | 360 | 74 | 7 | GO:0030135 | |
| GeneOntologyCellularComponent | membrane raft | 2.93e-04 | 362 | 74 | 7 | GO:0045121 | |
| GeneOntologyCellularComponent | membrane microdomain | 3.03e-04 | 364 | 74 | 7 | GO:0098857 | |
| GeneOntologyCellularComponent | lysosomal membrane | 1.24e-03 | 462 | 74 | 7 | GO:0005765 | |
| GeneOntologyCellularComponent | lytic vacuole membrane | 1.24e-03 | 462 | 74 | 7 | GO:0098852 | |
| GeneOntologyCellularComponent | vacuolar membrane | 2.10e-03 | 507 | 74 | 7 | GO:0005774 | |
| GeneOntologyCellularComponent | endocytic vesicle | 2.39e-03 | 384 | 74 | 6 | GO:0030139 | |
| GeneOntologyCellularComponent | transport vesicle | 2.39e-03 | 519 | 74 | 7 | GO:0030133 | |
| GeneOntologyCellularComponent | Golgi apparatus subcompartment | 4.82e-03 | 443 | 74 | 6 | GO:0098791 | |
| GeneOntologyCellularComponent | early endosome | 7.13e-03 | 481 | 74 | 6 | GO:0005769 | |
| MousePheno | spinal cord inflammation | 2.99e-15 | 8 | 33 | 6 | MP:0030987 | |
| MousePheno | decreased immature NK cell number | 1.05e-10 | 14 | 33 | 5 | MP:0013666 | |
| MousePheno | decreased mature NK cell number | 4.48e-10 | 18 | 33 | 5 | MP:0013672 | |
| MousePheno | abnormal immature NK cell number | 6.06e-10 | 19 | 33 | 5 | MP:0013665 | |
| MousePheno | abnormal immature NK cell morphology | 6.06e-10 | 19 | 33 | 5 | MP:0013699 | |
| MousePheno | decreased susceptibility to autoimmune diabetes | 8.17e-10 | 45 | 33 | 6 | MP:0004804 | |
| MousePheno | cystolithiasis | 1.37e-09 | 22 | 33 | 5 | MP:0011625 | |
| MousePheno | abnormal mature NK cell number | 2.20e-09 | 24 | 33 | 5 | MP:0013671 | |
| MousePheno | CNS inflammation | 2.55e-09 | 54 | 33 | 6 | MP:0006082 | |
| MousePheno | abnormal mature NK cell morphology | 2.74e-09 | 25 | 33 | 5 | MP:0013700 | |
| MousePheno | urolithiasis | 8.69e-09 | 31 | 33 | 5 | MP:0005360 | |
| MousePheno | demyelination | 4.10e-08 | 85 | 33 | 6 | MP:0000921 | |
| MousePheno | decreased gamma-delta T cell number | 7.63e-08 | 47 | 33 | 5 | MP:0008347 | |
| MousePheno | abnormal gamma-delta T cell number | 5.39e-07 | 69 | 33 | 5 | MP:0008345 | |
| MousePheno | decreased macrophage nitric oxide production | 9.97e-07 | 9 | 33 | 3 | MP:0011077 | |
| MousePheno | decreased activated T cell number | 9.97e-07 | 9 | 33 | 3 | MP:0001830 | |
| MousePheno | abnormal gamma-delta T cell morphology | 9.98e-07 | 78 | 33 | 5 | MP:0008343 | |
| MousePheno | increased NK cell number | 1.28e-06 | 82 | 33 | 5 | MP:0008044 | |
| MousePheno | abnormal myelination | 2.18e-06 | 166 | 33 | 6 | MP:0000920 | |
| MousePheno | abnormal macrophage nitric oxide production | 3.37e-06 | 13 | 33 | 3 | MP:0011074 | |
| MousePheno | decreased susceptibility to autoimmune disorder | 3.48e-06 | 180 | 33 | 6 | MP:0005351 | |
| MousePheno | decreased NK cell number | 8.40e-06 | 120 | 33 | 5 | MP:0008045 | |
| MousePheno | abnormal memory T cell physiology | 9.55e-06 | 18 | 33 | 3 | MP:0008051 | |
| MousePheno | decreased CD8-positive, alpha-beta T cell number | 1.05e-05 | 218 | 33 | 6 | MP:0008079 | |
| MousePheno | increased CD4-positive, alpha-beta T cell number | 1.85e-05 | 241 | 33 | 6 | MP:0008074 | |
| MousePheno | abnormal NK cell number | 4.78e-05 | 172 | 33 | 5 | MP:0008043 | |
| MousePheno | abnormal NK cell morphology | 6.42e-05 | 183 | 33 | 5 | MP:0005068 | |
| MousePheno | abnormal susceptibility to autoimmune disorder | 7.18e-05 | 307 | 33 | 6 | MP:0002425 | |
| MousePheno | abnormal T cell activation | 7.71e-05 | 311 | 33 | 6 | MP:0001828 | |
| MousePheno | increased alpha-beta T cell number | 7.71e-05 | 311 | 33 | 6 | MP:0012764 | |
| MousePheno | decreased alpha-beta T cell number | 8.27e-05 | 315 | 33 | 6 | MP:0012765 | |
| MousePheno | abnormal CD8-positive, alpha-beta T cell number | 1.52e-04 | 352 | 33 | 6 | MP:0008077 | |
| MousePheno | abnormal nitric oxide homeostasis | 1.70e-04 | 46 | 33 | 3 | MP:0003957 | |
| MousePheno | abnormal CD8-positive, alpha beta T cell morphology | 2.27e-04 | 379 | 33 | 6 | MP:0005010 | |
| MousePheno | abnormal urinary bladder morphology | 2.62e-04 | 247 | 33 | 5 | MP:0000538 | |
| MousePheno | abnormal CD4-positive, alpha-beta T cell number | 2.69e-04 | 391 | 33 | 6 | MP:0008073 | |
| MousePheno | autoimmune response | 2.96e-04 | 398 | 33 | 6 | MP:0001844 | |
| MousePheno | abnormal self tolerance | 3.04e-04 | 400 | 33 | 6 | MP:0005005 | |
| MousePheno | abnormal immune tolerance | 3.21e-04 | 404 | 33 | 6 | MP:0005000 | |
| MousePheno | increased susceptibility to Herpesvirales infection | 3.93e-04 | 61 | 33 | 3 | MP:0020916 | |
| MousePheno | impaired natural killer cell mediated cytotoxicity | 4.74e-04 | 65 | 33 | 3 | MP:0005070 | |
| MousePheno | abnormal CD4-positive, alpha beta T cell morphology | 4.87e-04 | 437 | 33 | 6 | MP:0002432 | |
| MousePheno | increased susceptibility to experimental autoimmune encephalomyelitis | 5.41e-04 | 68 | 33 | 3 | MP:0004799 | |
| MousePheno | abnormal natural killer cell mediated cytotoxicity | 6.14e-04 | 71 | 33 | 3 | MP:0011719 | |
| MousePheno | increased T cell number | 7.56e-04 | 475 | 33 | 6 | MP:0005015 | |
| MousePheno | abnormal cytotoxic T cell physiology | 8.39e-04 | 79 | 33 | 3 | MP:0005078 | |
| MousePheno | abnormal susceptibility to Herpesvirales infection | 9.68e-04 | 83 | 33 | 3 | MP:0020915 | |
| MousePheno | decreased susceptibility to experimental autoimmune encephalomyelitis | 9.68e-04 | 83 | 33 | 3 | MP:0004800 | |
| MousePheno | abnormal alpha-beta T cell number | 1.50e-03 | 542 | 33 | 6 | MP:0012763 | |
| MousePheno | abnormal CD8-positive, alpha-beta T cell physiology | 1.86e-03 | 104 | 33 | 3 | MP:0004392 | |
| MousePheno | abnormal response/metabolism to endogenous compounds | 1.86e-03 | 104 | 33 | 3 | MP:0003638 | |
| MousePheno | decreased T cell number | 1.87e-03 | 566 | 33 | 6 | MP:0005018 | |
| MousePheno | abnormal NK cell physiology | 2.07e-03 | 108 | 33 | 3 | MP:0010766 | |
| MousePheno | abnormal T cell physiology | 2.19e-03 | 584 | 33 | 6 | MP:0002444 | |
| MousePheno | increased lymphocyte cell number | 2.21e-03 | 797 | 33 | 7 | MP:0005013 | |
| MousePheno | increased mean corpuscular hemoglobin | 3.04e-03 | 258 | 33 | 4 | MP:0005561 | |
| MousePheno | abnormal effector T cell morphology | 3.17e-03 | 629 | 33 | 6 | MP:0002435 | |
| MousePheno | abnormal alpha-beta T cell morphology | 3.46e-03 | 640 | 33 | 6 | MP:0012762 | |
| Domain | - | ZNF132 ZNF17 ZNF134 ZNF19 ZSCAN5B ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF35 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 ZNF548 ZNF441 ZNF286A ZNF551 ZNF345 ZNF304 | 1.43e-48 | 679 | 76 | 47 | 3.30.160.60 |
| Domain | zf-C2H2 | ZNF132 ZNF17 ZNF134 ZNF19 ZSCAN5B ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF35 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 ZNF548 ZNF441 ZNF286A ZNF551 ZNF345 ZNF304 | 3.77e-48 | 693 | 76 | 47 | PF00096 |
| Domain | Znf_C2H2/integrase_DNA-bd | ZNF132 ZNF17 ZNF134 ZNF19 ZSCAN5B ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF35 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 ZNF548 ZNF441 ZNF286A ZNF551 ZNF345 ZNF304 | 4.03e-48 | 694 | 76 | 47 | IPR013087 |
| Domain | ZINC_FINGER_C2H2_2 | ZNF132 ZNF17 ZNF134 ZNF19 ZSCAN5B ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF35 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 ZNF548 ZNF441 ZNF286A ZNF551 ZNF345 ZNF304 | 7.54e-46 | 775 | 76 | 47 | PS50157 |
| Domain | ZINC_FINGER_C2H2_1 | ZNF132 ZNF17 ZNF134 ZNF19 ZSCAN5B ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF35 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 ZNF548 ZNF441 ZNF286A ZNF551 ZNF345 ZNF304 | 8.51e-46 | 777 | 76 | 47 | PS00028 |
| Domain | Znf_C2H2-like | ZNF132 ZNF17 ZNF134 ZNF19 ZSCAN5B ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF35 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 ZNF548 ZNF441 ZNF286A ZNF551 ZNF345 ZNF304 | 2.66e-45 | 796 | 76 | 47 | IPR015880 |
| Domain | Znf_C2H2 | ZNF132 ZNF17 ZNF134 ZNF19 ZSCAN5B ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF35 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 ZNF548 ZNF441 ZNF286A ZNF551 ZNF345 ZNF304 | 4.52e-45 | 805 | 76 | 47 | IPR007087 |
| Domain | ZnF_C2H2 | ZNF132 ZNF17 ZNF134 ZNF19 ZSCAN5B ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF35 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 ZNF548 ZNF441 ZNF286A ZNF551 ZNF345 ZNF304 | 5.39e-45 | 808 | 76 | 47 | SM00355 |
| Domain | KRAB | ZNF132 ZNF17 ZNF19 ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZIK1 ZNF211 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZNF300 ZFP28 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF548 ZNF441 ZNF286A ZNF551 ZNF304 | 7.85e-42 | 358 | 76 | 36 | PS50805 |
| Domain | KRAB | ZNF132 ZNF17 ZNF19 ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZIK1 ZNF211 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZNF300 ZFP28 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF548 ZNF441 ZNF286A ZNF551 ZNF304 | 7.85e-42 | 358 | 76 | 36 | PF01352 |
| Domain | KRAB | ZNF132 ZNF17 ZNF19 ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZIK1 ZNF211 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZNF300 ZFP28 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF548 ZNF441 ZNF286A ZNF551 ZNF304 | 2.41e-41 | 369 | 76 | 36 | SM00349 |
| Domain | KRAB | ZNF132 ZNF17 ZNF19 ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZIK1 ZNF211 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZNF300 ZFP28 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF548 ZNF441 ZNF286A ZNF551 ZNF304 | 2.67e-41 | 370 | 76 | 36 | IPR001909 |
| Domain | zf-C2H2_6 | ZNF17 ZSCAN5B ZNF671 ZFP90 ZNF773 ZNF211 ZNF789 ZNF530 ZNF792 ZNF570 ZNF587 ZNF256 ZSCAN9 ZFP28 ZNF225 ZNF227 ZNF333 ZNF418 ZNF417 ZNF865 ZNF548 ZNF286A ZNF551 ZNF345 | 1.84e-24 | 314 | 76 | 24 | PF13912 |
| Domain | MHC_I_C | 5.84e-12 | 6 | 76 | 5 | PF06623 | |
| Domain | MHC_I_a_C | 5.84e-12 | 6 | 76 | 5 | IPR010579 | |
| Domain | MHC_I | 1.92e-10 | 21 | 76 | 6 | PF00129 | |
| Domain | MHC_I_a_a1/a2 | 1.92e-10 | 21 | 76 | 6 | IPR001039 | |
| Domain | zf-H2C2_2 | 1.90e-09 | 14 | 76 | 5 | PF13465 | |
| Domain | - | 3.91e-08 | 24 | 76 | 5 | 3.30.500.10 | |
| Domain | MHC_I-like_Ag-recog | 3.91e-08 | 24 | 76 | 5 | IPR011161 | |
| Domain | C1-set | 8.21e-08 | 54 | 76 | 6 | PF07654 | |
| Domain | IGc1 | 1.03e-07 | 56 | 76 | 6 | SM00407 | |
| Domain | Ig_C1-set | 1.27e-07 | 58 | 76 | 6 | IPR003597 | |
| Domain | Ig/MHC_CS | 1.27e-07 | 58 | 76 | 6 | IPR003006 | |
| Domain | IG_MHC | 1.56e-07 | 60 | 76 | 6 | PS00290 | |
| Domain | MHC_I/II-like_Ag-recog | 4.41e-07 | 38 | 76 | 5 | IPR011162 | |
| Domain | 6Phosfructo_kin | 9.75e-05 | 4 | 76 | 2 | IPR013079 | |
| Domain | 6PF2K | 9.75e-05 | 4 | 76 | 2 | PF01591 | |
| Domain | 6Pfruct_kin | 9.75e-05 | 4 | 76 | 2 | IPR003094 | |
| Domain | PG/BPGM_mutase_AS | 5.77e-04 | 9 | 76 | 2 | IPR001345 | |
| Domain | PGAM | 7.20e-04 | 10 | 76 | 2 | SM00855 | |
| Domain | PG_MUTASE | 7.20e-04 | 10 | 76 | 2 | PS00175 | |
| Domain | IG_LIKE | 8.49e-04 | 491 | 76 | 8 | PS50835 | |
| Domain | Ig-like_dom | 9.91e-04 | 503 | 76 | 8 | IPR007110 | |
| Domain | His_Pase_superF_clade-1 | 1.05e-03 | 12 | 76 | 2 | IPR013078 | |
| Domain | His_Phos_1 | 1.05e-03 | 12 | 76 | 2 | PF00300 | |
| Domain | SCAN | 1.54e-03 | 56 | 76 | 3 | SM00431 | |
| Domain | SCAN_BOX | 1.70e-03 | 58 | 76 | 3 | PS50804 | |
| Domain | SCAN | 1.70e-03 | 58 | 76 | 3 | PF02023 | |
| Domain | SCAN_dom | 1.70e-03 | 58 | 76 | 3 | IPR003309 | |
| Domain | Retrov_capsid_C | 1.79e-03 | 59 | 76 | 3 | IPR008916 | |
| Domain | Ig-like_fold | 2.22e-03 | 706 | 76 | 9 | IPR013783 | |
| Domain | His_PPase_superfam | 2.96e-03 | 20 | 76 | 2 | IPR029033 | |
| Domain | - | 2.96e-03 | 20 | 76 | 2 | 3.40.50.1240 | |
| Domain | - | 5.45e-03 | 663 | 76 | 8 | 2.60.40.10 | |
| Pathway | REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION | ZNF17 ZNF19 ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF530 ZNF792 ZNF268 ZNF570 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZNF300 ZFP28 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 TAF1L ZNF548 ZNF441 ZNF286A ZNF551 ZNF304 | 5.56e-22 | 1387 | 59 | 36 | M734 |
| Pathway | REACTOME_ENDOSOMAL_VACUOLAR_PATHWAY | 3.44e-13 | 9 | 59 | 6 | MM14527 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_KSHV_MIR1_2_TO_ANTIGEN_PROCESSING_AND_PRESENTATION_BY_MHC_CLASS_I_MOLECULES | 6.46e-12 | 6 | 59 | 5 | M47468 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HPV_E5_TO_ANTIGEN_PROCESSING_AND_PRESENTATION_BY_MHC_CLASS_I_MOLECULES | 2.25e-11 | 7 | 59 | 5 | M47530 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HTLV_1_P12_TO_ANTIGEN_PROCESSING_AND_PRESENTATION_BY_MHC_CLASS_I_MOLECULES | 2.25e-11 | 7 | 59 | 5 | M47582 | |
| Pathway | REACTOME_ER_PHAGOSOME_PATHWAY | 7.39e-11 | 18 | 59 | 6 | MM14525 | |
| Pathway | BIOCARTA_CTL_PATHWAY | 1.53e-10 | 20 | 59 | 6 | MM1374 | |
| Pathway | REACTOME_ENDOSOMAL_VACUOLAR_PATHWAY | 4.89e-10 | 11 | 59 | 5 | M525 | |
| Pathway | BIOCARTA_NKCELLS_PATHWAY | 6.89e-10 | 25 | 59 | 6 | MM1465 | |
| Pathway | REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC | 6.89e-10 | 25 | 59 | 6 | MM15713 | |
| Pathway | KEGG_MEDICUS_REFERENCE_ANTIGEN_PROCESSING_AND_PRESENTATION_BY_MHC_CLASS_I_MOLECULES | 8.36e-10 | 12 | 59 | 5 | M47529 | |
| Pathway | REACTOME_GENERIC_TRANSCRIPTION_PATHWAY | ZFP90 ZNF773 ZIK1 ZNF268 ZFP1 ZNF189 ZNF286B ZNF300 ZFP28 ZNF221 ZNF112 ZNF235 ZNF418 TAF1L ZNF286A ZNF551 | 6.24e-08 | 768 | 59 | 16 | MM14851 |
| Pathway | REACTOME_DAP12_INTERACTIONS | 9.15e-08 | 54 | 59 | 6 | MM14871 | |
| Pathway | REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC | 1.19e-07 | 29 | 59 | 5 | M1062 | |
| Pathway | KEGG_ALLOGRAFT_REJECTION | 4.25e-07 | 37 | 59 | 5 | M18615 | |
| Pathway | REACTOME_GENE_EXPRESSION_TRANSCRIPTION | MYBBP1A ZFP90 ZNF773 ZIK1 ZNF268 ZFP1 ZNF189 ZNF286B ZNF300 ZFP28 ZNF221 ZNF112 ZNF235 ZNF418 TAF1L ZNF286A ZNF551 | 5.58e-07 | 1022 | 59 | 17 | MM15436 |
| Pathway | KEGG_GRAFT_VERSUS_HOST_DISEASE | 7.21e-07 | 41 | 59 | 5 | M13519 | |
| Pathway | REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION | 7.22e-07 | 76 | 59 | 6 | MM14526 | |
| Pathway | REACTOME_INTERFERON_ALPHA_BETA_SIGNALING | 8.42e-07 | 78 | 59 | 6 | M973 | |
| Pathway | KEGG_TYPE_I_DIABETES_MELLITUS | 9.21e-07 | 43 | 59 | 5 | M12617 | |
| Pathway | KEGG_AUTOIMMUNE_THYROID_DISEASE | 2.42e-06 | 52 | 59 | 5 | M13103 | |
| Pathway | REACTOME_INTERFERON_GAMMA_SIGNALING | 3.24e-06 | 98 | 59 | 6 | M965 | |
| Pathway | WP_PROTEASOME_DEGRADATION | 3.50e-06 | 56 | 59 | 5 | MM15901 | |
| Pathway | WP_PROTEASOME_DEGRADATION | 5.82e-06 | 62 | 59 | 5 | M39639 | |
| Pathway | WP_TAR_SYNDROME | 6.31e-06 | 63 | 59 | 5 | M48082 | |
| Pathway | KEGG_VIRAL_MYOCARDITIS | 1.06e-05 | 70 | 59 | 5 | M12294 | |
| Pathway | REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL | 2.05e-05 | 135 | 59 | 6 | MM14781 | |
| Pathway | KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION | 3.25e-05 | 88 | 59 | 5 | M16004 | |
| Pathway | WP_ALLOGRAFT_REJECTION | 3.43e-05 | 89 | 59 | 5 | M39398 | |
| Pathway | REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION | 7.93e-05 | 106 | 59 | 5 | M518 | |
| Pathway | REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION | 8.51e-05 | 343 | 59 | 8 | MM15712 | |
| Pathway | REACTOME_SARS_COV_2_ACTIVATES_MODULATES_INNATE_AND_ADAPTIVE_IMMUNE_RESPONSES | 1.79e-04 | 126 | 59 | 5 | M45009 | |
| Pathway | WP_EBOLA_VIRUS_INFECTION_IN_HOST | 2.00e-04 | 129 | 59 | 5 | M39693 | |
| Pathway | KEGG_CELL_ADHESION_MOLECULES_CAMS | 2.31e-04 | 133 | 59 | 5 | M16476 | |
| Pathway | KEGG_ENDOCYTOSIS | 9.43e-04 | 181 | 59 | 5 | M1519 | |
| Pathway | REACTOME_INTERFERON_SIGNALING | 9.52e-04 | 273 | 59 | 6 | M983 | |
| Pathway | REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION | 1.01e-03 | 381 | 59 | 7 | M1066 | |
| Pathway | REACTOME_REGULATION_OF_GLYCOLYSIS_BY_FRUCTOSE_2_6_BISPHOSPHATE_METABOLISM | 1.11e-03 | 12 | 59 | 2 | M27950 | |
| Pathway | REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL | 1.17e-03 | 190 | 59 | 5 | M8240 | |
| Pathway | REACTOME_SARS_COV_2_HOST_INTERACTIONS | 1.60e-03 | 204 | 59 | 5 | M45011 | |
| Pathway | KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY | 2.57e-03 | 137 | 59 | 4 | M5669 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 6088985 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 1686840 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 1705528 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 2808323 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 21088134 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 34181639 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 69663 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 8206527 | ||
| Pubmed | Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. | 6.22e-16 | 7 | 76 | 6 | 12459592 | |
| Pubmed | Multiple sequences related to classical histocompatibility antigens in the mouse genome. | 6.22e-16 | 7 | 76 | 6 | 6264319 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 3456611 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 15809355 | ||
| Pubmed | Sequence analysis of the C3H H-2K1k gene: relationship to the H-2 loci. | 6.22e-16 | 7 | 76 | 6 | 2714856 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 10500200 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 16210630 | ||
| Pubmed | Structural analysis of H-2Kf and H-2Kfm1 by using H-2K locus-specific sequences. | 6.22e-16 | 7 | 76 | 6 | 2391419 | |
| Pubmed | Thymus-leukemia (TL) antigens of the mouse. Analysis of TL mRNA and TL cDNA TL+ and TL- strains. | 6.22e-16 | 7 | 76 | 6 | 3840195 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 15671142 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 14215561 | ||
| Pubmed | Tolerance and MHC restriction in transgenic mice expressing a MHC class I gene in erythroid cells. | 6.22e-16 | 7 | 76 | 6 | 1540549 | |
| Pubmed | Mouse histocompatibility genes: structure and organisation of a Kd gene. | 6.22e-16 | 7 | 76 | 6 | 11894934 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 19700752 | ||
| Pubmed | A saturation hypothesis to explain both enhanced and impaired learning with enhanced plasticity. | 6.22e-16 | 7 | 76 | 6 | 28234229 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 11894963 | ||
| Pubmed | Interaction of H-2Db with mutant histocompatibility gene H (KH-11) in the mouse. | 6.22e-16 | 7 | 76 | 6 | 6242891 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 16836618 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 22287714 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 17512611 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 3997208 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 3263465 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 7018573 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 2997361 | ||
| Pubmed | Expression of GM1 and GD1a in mouse liver is linked to the H-2 complex on chromosome 17. | 6.22e-16 | 7 | 76 | 6 | 6671979 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 18974374 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 9869916 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 16148128 | ||
| Pubmed | The role of the MHC on resistance to group a streptococci in mice. | 6.22e-16 | 7 | 76 | 6 | 16148132 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 312902 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 2642506 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 9037062 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 1840571 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 16476767 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 16148097 | ||
| Pubmed | Serological analysis of H-2 mutations using monoclonal antibodies. | 6.22e-16 | 7 | 76 | 6 | 6084033 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 20957233 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 11580250 | ||
| Pubmed | V beta T cell repertoire of CD8+ splenocytes selected on nonpolymorphic MHC class I molecules. | 6.22e-16 | 7 | 76 | 6 | 11086076 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 24101547 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 12682111 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 3335396 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 12750360 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 6689056 | ||
| Pubmed | The multi-locus H-2Dw16 region has an organization distinct from the Dd region. | 6.22e-16 | 7 | 76 | 6 | 1348492 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 16461341 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 18416856 | ||
| Pubmed | Convergent recombination shapes the clonotypic landscape of the naive T-cell repertoire. | 6.22e-16 | 7 | 76 | 6 | 20974936 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 10704462 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 6895187 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 22573867 | ||
| Pubmed | Genetic control of corticosteroid side-chain isomerase activity in the mouse. | 6.22e-16 | 7 | 76 | 6 | 6822218 | |
| Pubmed | A novel H-2K splice form: predictions for other alternative H-2 splicing events. | 6.22e-16 | 7 | 76 | 6 | 2908875 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 15210799 | ||
| Pubmed | Comparison of exon 5 sequences from 35 class I genes of the BALB/c mouse. | 6.22e-16 | 7 | 76 | 6 | 2584927 | |
| Pubmed | Studies of two H-2Db mutants: B6. C-H-2bm13 and B6.C-H-2bm14. | 6.22e-16 | 7 | 76 | 6 | 6159320 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 3496275 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 12147629 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 3458188 | ||
| Pubmed | NK gene complex and chromosome 19 loci enhance MHC resistance to murine cytomegalovirus infection. | 6.22e-16 | 7 | 76 | 6 | 19820922 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 19462379 | ||
| Pubmed | Structural diversity of the classical H-2 genes: K, D, and L. | 6.22e-16 | 7 | 76 | 6 | 1730883 | |
| Pubmed | Synapse elimination and learning rules co-regulated by MHC class I H2-Db. | 6.22e-16 | 7 | 76 | 6 | 24695230 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 8181071 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 3680952 | ||
| Pubmed | Thymus leukemia antigen controls intraepithelial lymphocyte function and inflammatory bowel disease. | 6.22e-16 | 7 | 76 | 6 | 19004778 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 6300887 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 23142461 | ||
| Pubmed | Structure of C-terminal half of two H-2 antigens from cloned mRNA. | 6.22e-16 | 7 | 76 | 6 | 6895103 | |
| Pubmed | H-2-linked regulation of xenotropic murine leukemia virus expression. | 6.22e-16 | 7 | 76 | 6 | 6300850 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 3094964 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 8500526 | ||
| Pubmed | The nucleotide sequence and comparative analysis of the H-2Dp class I H-2 gene. | 6.22e-16 | 7 | 76 | 6 | 3082989 | |
| Pubmed | Expression of H-2K and H-2D genes by PYS-2 teratocarcinoma cells. | 6.22e-16 | 7 | 76 | 6 | 3202874 | |
| Pubmed | cDNA clone coding for part of a mouse H-2d major histocompatibility antigen. | 6.22e-16 | 7 | 76 | 6 | 6265910 | |
| Pubmed | Cutting edge: MHC class I-Ly49 interaction regulates neuronal function. | 6.22e-16 | 7 | 76 | 6 | 18453559 | |
| Pubmed | DNA polymorphisms defined by the Tu108 probe map to the Tla region of mouse chromosome 17. | 6.22e-16 | 7 | 76 | 6 | 2906539 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 7675041 | ||
| Pubmed | Nucleotide sequences of H2g7 K and D loci of nonobese diabetic mice. | 6.22e-16 | 7 | 76 | 6 | 7759137 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 3013627 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 6799575 | ||
| Pubmed | Qa antigen expression on functional lymphoid, myeloid, and stem cells in adult mice. | 6.22e-16 | 7 | 76 | 6 | 6966299 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 12140378 | ||
| Pubmed | Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. | 6.22e-16 | 7 | 76 | 6 | 11854356 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 2410925 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 11842259 | ||
| Pubmed | DNA sequence of the mouse H-2Dd transplantation antigen gene. | 6.22e-16 | 7 | 76 | 6 | 3856254 | |
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 12421934 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 3894562 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 27385590 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 3840763 | ||
| Pubmed | 6.22e-16 | 7 | 76 | 6 | 12421940 | ||
| Interaction | TRIM28 interactions | ZNF17 ZNF19 ZNF776 MYBBP1A ZFP90 ZNF773 ZNF211 ZNF789 HLA-B ZNF792 ZNF268 ZNF587 ZNF256 ZFP1 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF441 ZNF304 | 1.05e-08 | 1474 | 75 | 22 | int:TRIM28 |
| Interaction | LILRB1 interactions | 3.65e-08 | 10 | 75 | 4 | int:LILRB1 | |
| Interaction | LILRB2 interactions | 3.65e-08 | 10 | 75 | 4 | int:LILRB2 | |
| Interaction | HLA-G interactions | 2.82e-07 | 118 | 75 | 7 | int:HLA-G | |
| Interaction | HLA-H interactions | 4.06e-07 | 17 | 75 | 4 | int:HLA-H | |
| Interaction | HLA-E interactions | 4.86e-07 | 79 | 75 | 6 | int:HLA-E | |
| Interaction | TRIM41 interactions | 1.77e-06 | 223 | 75 | 8 | int:TRIM41 | |
| Interaction | CD8A interactions | 2.49e-06 | 26 | 75 | 4 | int:CD8A | |
| Interaction | TRIM39 interactions | 3.07e-06 | 108 | 75 | 6 | int:TRIM39 | |
| Interaction | CEP70 interactions | 5.83e-06 | 262 | 75 | 8 | int:CEP70 | |
| Interaction | ZNF250 interactions | 7.50e-06 | 126 | 75 | 6 | int:ZNF250 | |
| Interaction | ZNF837 interactions | 1.13e-05 | 79 | 75 | 5 | int:ZNF837 | |
| Interaction | GOLGA6L9 interactions | 1.58e-05 | 216 | 75 | 7 | int:GOLGA6L9 | |
| Interaction | B2M interactions | 2.38e-05 | 92 | 75 | 5 | int:B2M | |
| Interaction | ZNF547 interactions | 3.24e-05 | 17 | 75 | 3 | int:ZNF547 | |
| Interaction | KRT40 interactions | ZNF17 TRIM42 ZNF792 ZNF268 ZNF587 ZFP1 ZNF417 ZNF865 ZNF286A | 3.28e-05 | 434 | 75 | 9 | int:KRT40 |
| Interaction | CCDC136 interactions | 3.97e-05 | 169 | 75 | 6 | int:CCDC136 | |
| Interaction | HOOK2 interactions | 5.64e-05 | 180 | 75 | 6 | int:HOOK2 | |
| Interaction | ZYG11A interactions | 6.27e-05 | 21 | 75 | 3 | int:ZYG11A | |
| Interaction | MTUS2 interactions | 6.91e-05 | 370 | 75 | 8 | int:MTUS2 | |
| Interaction | ADAM21 interactions | 9.49e-05 | 64 | 75 | 4 | int:ADAM21 | |
| Interaction | SLC9A8 interactions | 1.07e-04 | 25 | 75 | 3 | int:SLC9A8 | |
| Interaction | KRTAP10-7 interactions | 1.09e-04 | 293 | 75 | 7 | int:KRTAP10-7 | |
| Interaction | HLA-DRB3 interactions | 1.14e-04 | 67 | 75 | 4 | int:HLA-DRB3 | |
| Interaction | CCDC125 interactions | 1.14e-04 | 67 | 75 | 4 | int:CCDC125 | |
| Interaction | NUDT22 interactions | 1.21e-04 | 26 | 75 | 3 | int:NUDT22 | |
| Interaction | MCC interactions | 1.50e-04 | 215 | 75 | 6 | int:MCC | |
| Interaction | ZNF438 interactions | 1.50e-04 | 72 | 75 | 4 | int:ZNF438 | |
| Interaction | AXIN2 interactions | 1.59e-04 | 73 | 75 | 4 | int:AXIN2 | |
| Interaction | ZNF286A interactions | 1.87e-04 | 30 | 75 | 3 | int:ZNF286A | |
| Interaction | ZNF71 interactions | 2.15e-04 | 79 | 75 | 4 | int:ZNF71 | |
| Interaction | ZBTB8A interactions | 2.37e-04 | 81 | 75 | 4 | int:ZBTB8A | |
| Interaction | HLA-DQB1 interactions | 2.48e-04 | 82 | 75 | 4 | int:HLA-DQB1 | |
| Interaction | HLA-B interactions | 2.66e-04 | 239 | 75 | 6 | int:HLA-B | |
| Interaction | ZNF225 interactions | 2.84e-04 | 7 | 75 | 2 | int:ZNF225 | |
| Interaction | HLA-F interactions | 2.98e-04 | 86 | 75 | 4 | int:HLA-F | |
| Interaction | KRTAP10-6 interactions | 3.26e-04 | 88 | 75 | 4 | int:KRTAP10-6 | |
| Interaction | KRTAP10-5 interactions | 3.27e-04 | 160 | 75 | 5 | int:KRTAP10-5 | |
| Interaction | HLA-C interactions | 3.41e-04 | 353 | 75 | 7 | int:HLA-C | |
| Interaction | ZNF112 interactions | 3.77e-04 | 8 | 75 | 2 | int:ZNF112 | |
| Interaction | TAP2 interactions | 4.19e-04 | 94 | 75 | 4 | int:TAP2 | |
| Interaction | CDR2L interactions | 4.36e-04 | 95 | 75 | 4 | int:CDR2L | |
| Interaction | MAP3K20 interactions | 5.10e-04 | 99 | 75 | 4 | int:MAP3K20 | |
| Interaction | ZNF417 interactions | 5.32e-04 | 178 | 75 | 5 | int:ZNF417 | |
| Interaction | ZNF221 interactions | 6.03e-04 | 10 | 75 | 2 | int:ZNF221 | |
| Interaction | KLRD1 interactions | 6.14e-04 | 104 | 75 | 4 | int:KLRD1 | |
| Interaction | MRFAP1L1 interactions | 8.11e-04 | 112 | 75 | 4 | int:MRFAP1L1 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr19q13 | ZNF132 ZNF17 ZNF134 ZSCAN5B ZNF776 ZNF671 ZNF773 ZNF547 ZIK1 ZNF211 ZNF530 ZNF792 ZNF570 ZNF175 ZNF587 ZNF256 ZFP28 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF418 ZNF417 ZNF865 ZNF548 ZNF551 ZNF345 ZNF304 | 7.78e-28 | 1192 | 76 | 30 | chr19q13 |
| Cytoband | 19q13.43 | ZSCAN5B ZNF776 ZNF671 ZNF773 ZNF547 ZIK1 ZNF530 ZNF587 ZNF256 ZNF772 ZNF418 ZNF417 ZNF548 ZNF551 | 1.60e-24 | 87 | 76 | 14 | 19q13.43 |
| Cytoband | 19q13.4 | 4.25e-09 | 79 | 76 | 6 | 19q13.4 | |
| Cytoband | 6p21.3 | 2.07e-07 | 250 | 76 | 7 | 6p21.3 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr6p22 | 3.26e-06 | 378 | 76 | 7 | chr6p22 | |
| Cytoband | 19q13.2 | 1.65e-04 | 164 | 76 | 4 | 19q13.2 | |
| Cytoband | 19q13.12 | 6.41e-03 | 72 | 76 | 2 | 19q13.12 | |
| GeneFamily | Zinc fingers C2H2-type|ZF class homeoboxes and pseudogenes | ZNF132 ZNF17 ZNF134 ZNF19 ZSCAN5B ZNF776 ZNF671 ZFP90 ZNF773 ZNF547 ZNF143 ZIK1 ZNF211 ZNF35 ZNF789 ZNF530 ZNF792 ZNF268 ZNF570 ZNF648 ZNF175 ZNF587 ZNF256 ZFP1 ZNF189 ZSCAN9 ZNF286B ZNF300 ZFP28 ZNF397 ZNF221 ZNF772 ZNF225 ZNF227 ZNF112 ZNF235 ZNF333 ZNF418 ZNF417 ZNF623 ZNF865 ZNF548 ZNF441 ZNF286A ZNF551 ZNF345 ZNF304 | 8.87e-51 | 718 | 67 | 47 | 28 |
| GeneFamily | Histocompatibility complex|C1-set domain containing | 1.30e-08 | 44 | 67 | 6 | 588 | |
| GeneFamily | C1-set domain containing | 4.59e-07 | 42 | 67 | 5 | 591 | |
| GeneFamily | 6-phosphofructo-2-kinases/fructose-2,6-biphosphatases | 8.08e-05 | 4 | 67 | 2 | 1077 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_ENDOTHELIAL_CELL_OF_LYMPHATIC_VESSEL_AGEING | 3.50e-12 | 16 | 75 | 6 | MM3766 | |
| Coexpression | WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_DN | 1.18e-11 | 19 | 75 | 6 | MM797 | |
| Coexpression | MIKKELSEN_NPC_ICP_WITH_H3K27ME3 | 1.18e-11 | 19 | 75 | 6 | MM862 | |
| Coexpression | TABULA_MURIS_SENIS_BLADDER_LEUKOCYTE_AGEING | 1.68e-11 | 20 | 75 | 6 | MM3682 | |
| Coexpression | RUAN_RESPONSE_TO_TNF_UP | 2.35e-11 | 21 | 75 | 6 | MM651 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_PULMONARY_INTERSTITIAL_FIBROBLAST_AGEING | 5.78e-11 | 24 | 75 | 6 | MM3773 | |
| Coexpression | RUAN_RESPONSE_TO_TNF_TROGLITAZONE_UP | 7.59e-11 | 25 | 75 | 6 | MM672 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_KIDNEY_MESANGIAL_CELL_AGEING | 3.11e-10 | 31 | 75 | 6 | MM3729 | |
| Coexpression | PAL_PRMT5_TARGETS_DN | 6.80e-10 | 35 | 75 | 6 | MM674 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_CD8_POSITIVE_ALPHA_BETA_T_CELL_AGEING | 1.35e-09 | 39 | 75 | 6 | MM3758 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_KIDNEY_CORTEX_ARTERY_CELL_AGEING | 1.35e-09 | 39 | 75 | 6 | MM3725 | |
| Coexpression | GAURNIER_PSMD4_TARGETS | 1.65e-09 | 73 | 75 | 7 | M11428 | |
| Coexpression | HOWLIN_CITED1_TARGETS_1_UP | 1.86e-09 | 41 | 75 | 6 | MM710 | |
| Coexpression | HU_GENOTOXIC_DAMAGE_4HR | 2.51e-09 | 43 | 75 | 6 | MM1204 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_TYPE_II_PNEUMOCYTE_AGEING | 2.90e-09 | 44 | 75 | 6 | MM3775 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_AND_AORTA_ENDOCARDIAL_CELL_AGEING | 3.83e-09 | 46 | 75 | 6 | MM3712 | |
| Coexpression | BAUS_TFF2_TARGETS_UP | 5.68e-09 | 49 | 75 | 6 | MM1287 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_MEGAKARYOCYTE_ERYTHROID_PROGENITOR_CELL_AGEING | 6.44e-09 | 50 | 75 | 6 | MM3805 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_NAIVE_T_CELL_AGEING | 8.21e-09 | 52 | 75 | 6 | MM3808 | |
| Coexpression | TABULA_MURIS_SENIS_TONGUE_KERATINOCYTE_AGEING | 1.30e-08 | 56 | 75 | 6 | MM3852 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_AND_AORTA_SMOOTH_MUSCLE_CELL_AGEING | 1.45e-08 | 57 | 75 | 6 | MM3716 | |
| Coexpression | TABULA_MURIS_SENIS_BRAIN_NON_MYELOID_INTERNEURON_AGEING | 1.79e-08 | 59 | 75 | 6 | MM3688 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_ENDOCARDIAL_CELL_AGEING | 1.79e-08 | 59 | 75 | 6 | MM3704 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_GRANULOCYTE_AGEING | 7.11e-08 | 74 | 75 | 6 | MM3796 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_NK_CELL_AGEING | 7.71e-08 | 75 | 75 | 6 | MM3759 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_BRUSH_CELL_AGEING | 7.71e-08 | 75 | 75 | 6 | MM3718 | |
| Coexpression | TABULA_MURIS_SENIS_MESENTERIC_ADIPOSE_TISSUE_B_CELL_AGEING | 1.32e-07 | 82 | 75 | 6 | MM3777 | |
| Coexpression | TABULA_MURIS_SENIS_TRACHEA_MACROPHAGE_AGEING | 1.32e-07 | 82 | 75 | 6 | MM3858 | |
| Coexpression | WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_UP | 1.52e-07 | 84 | 75 | 6 | MM1049 | |
| Coexpression | HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_DN | 1.67e-07 | 44 | 75 | 5 | MM805 | |
| Coexpression | MIKKELSEN_MCV6_ICP_WITH_H3K27ME3 | 1.76e-07 | 86 | 75 | 6 | MM834 | |
| Coexpression | LEE_CALORIE_RESTRICTION_NEOCORTEX_UP | 1.88e-07 | 87 | 75 | 6 | MM652 | |
| Coexpression | CASTELLANO_NRAS_TARGETS_UP | 2.01e-07 | 88 | 75 | 6 | MM1087 | |
| Coexpression | COATES_MACROPHAGE_M1_VS_M2_DN | 2.30e-07 | 90 | 75 | 6 | MM750 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_B_CELL_AGEING | 2.30e-07 | 90 | 75 | 6 | MM3756 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_FENESTRATED_CELL_AGEING | 2.46e-07 | 91 | 75 | 6 | MM3720 | |
| Coexpression | TABULA_MURIS_SENIS_LIMB_MUSCLE_SMOOTH_MUSCLE_CELL_AGEING | 2.63e-07 | 92 | 75 | 6 | MM3748 | |
| Coexpression | JACKSON_DNMT1_TARGETS_UP | 2.80e-07 | 93 | 75 | 6 | MM1185 | |
| Coexpression | TABULA_MURIS_SENIS_SPLEEN_NK_CELL_AGEING | 3.38e-07 | 96 | 75 | 6 | MM3834 | |
| Coexpression | TABULA_MURIS_SENIS_MAMMARY_GLAND_MACROPHAGE_AGEING | 3.60e-07 | 97 | 75 | 6 | MM3789 | |
| Coexpression | ZEMEK_IMMUNE_CHECKPOINT_BLOCKADE_OVARIAN_CANCER_OVERLAP_UP | 3.83e-07 | 98 | 75 | 6 | MM460 | |
| Coexpression | HOLLERN_MICROACINAR_BREAST_TUMOR_UP | 3.92e-07 | 52 | 75 | 5 | MM968 | |
| Coexpression | VERHAAK_GLIOBLASTOMA_CLASSICAL | 4.05e-07 | 161 | 75 | 7 | M2121 | |
| Coexpression | ZEMEK_IMMUNE_CHECKPOINT_BLOCKADE_OVARIAN_CANCER_RENCA_UP | 4.31e-07 | 100 | 75 | 6 | MM458 | |
| Coexpression | SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4 | 4.32e-07 | 330 | 75 | 9 | MM1120 | |
| Coexpression | GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN | 5.14e-07 | 103 | 75 | 6 | MM476 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_PROMONOCYTE_AGEING | 5.44e-07 | 104 | 75 | 6 | MM3812 | |
| Coexpression | HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_24HR | 6.82e-07 | 58 | 75 | 5 | MM661 | |
| Coexpression | TABULA_MURIS_SENIS_SPLEEN_B_CELL_AGEING | 7.99e-07 | 111 | 75 | 6 | MM3831 | |
| Coexpression | LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_POLYSACCHARIDE_ANTIBODY_3DY_POSITIVE | 8.09e-07 | 60 | 75 | 5 | M40971 | |
| Coexpression | ZHANG_UTERUS_C9_DENDRITIC_CELL | 9.35e-07 | 114 | 75 | 6 | MM16615 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_HEMATOPOIETIC_PRECURSOR_CELL_AGEING | 9.35e-07 | 114 | 75 | 6 | MM3799 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_VENTRICULAR_MYOCYTE_AGEING | 1.26e-06 | 120 | 75 | 6 | MM3710 | |
| Coexpression | GSE18893_TCONV_VS_TREG_2H_TNF_STIM_DN | 1.42e-06 | 194 | 75 | 7 | M7306 | |
| Coexpression | AFFAR_YY1_TARGETS_DN | 1.51e-06 | 283 | 75 | 8 | MM1157 | |
| Coexpression | YU_MYC_TARGETS_DN | 1.52e-06 | 68 | 75 | 5 | MM632 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_KIDNEY_DISTAL_CONVOLUTED_TUBULE_EPITHELIAL_CELL_AGEING | 1.53e-06 | 124 | 75 | 6 | MM3726 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_AND_AORTA_CARDIOMYOCYTE_AGEING | 1.68e-06 | 126 | 75 | 6 | MM3711 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_VALVE_CELL_AGEING | 1.68e-06 | 126 | 75 | 6 | MM3709 | |
| Coexpression | MA_RAT_AGING_UP | 1.76e-06 | 127 | 75 | 6 | MM16096 | |
| Coexpression | TABULA_MURIS_SENIS_TRACHEA_FIBROBLAST_AGEING | 1.76e-06 | 127 | 75 | 6 | MM3856 | |
| Coexpression | MIKKELSEN_IPS_ICP_WITH_H3K4ME3_AND_H327ME3 | 2.20e-06 | 132 | 75 | 6 | MM841 | |
| Coexpression | TABULA_MURIS_SENIS_LIMB_MUSCLE_SKELETAL_MUSCLE_SATELLITE_CELL_AGEING | 2.62e-06 | 136 | 75 | 6 | MM3747 | |
| Coexpression | ZHANG_UTERUS_C6_ENDOTHELIAL_PLVAP_HIGH_CELL | 2.74e-06 | 137 | 75 | 6 | MM16612 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_ENDOTHELIAL_CELL_OF_CORONARY_ARTERY_AGEING | 3.10e-06 | 140 | 75 | 6 | MM3705 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_CD4_POSITIVE_ALPHA_BETA_T_CELL_AGEING | 3.37e-06 | 142 | 75 | 6 | MM3757 | |
| Coexpression | TABULA_MURIS_SENIS_AORTA_PROFESSIONAL_ANTIGEN_PRESENTING_CELL_AGEING | 3.51e-06 | 143 | 75 | 6 | MM3673 | |
| Coexpression | TABULA_MURIS_SENIS_LIMB_MUSCLE_ENDOTHELIAL_CELL_AGEING | 3.80e-06 | 145 | 75 | 6 | MM3744 | |
| Coexpression | MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3 | 3.95e-06 | 146 | 75 | 6 | MM856 | |
| Coexpression | TABULA_MURIS_SENIS_LIVER_HEPATOCYTE_AGEING | 4.11e-06 | 147 | 75 | 6 | MM3753 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_MONOCYTE_AGEING | 4.11e-06 | 147 | 75 | 6 | MM3707 | |
| Coexpression | YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_9 | 4.60e-06 | 85 | 75 | 5 | MM1279 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_BRONCHIAL_SMOOTH_MUSCLE_CELL_AGEING | 5.79e-06 | 156 | 75 | 6 | MM3763 | |
| Coexpression | TABULA_MURIS_SENIS_TONGUE_BASAL_CELL_OF_EPIDERMIS_AGEING | 6.23e-06 | 158 | 75 | 6 | MM3851 | |
| Coexpression | TABULA_MURIS_SENIS_BLADDER_BLADDER_UROTHELIAL_CELL_AGEING | 7.72e-06 | 164 | 75 | 6 | MM3680 | |
| Coexpression | ZHANG_UTERUS_C8_NK_CELL | 8.86e-06 | 168 | 75 | 6 | MM16614 | |
| Coexpression | KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP | ZNF671 ZNF211 ZNF789 HLA-A CPEB4 HLA-E HLA-F HLA-G ZNF397 ZNF623 ENTPD4 | 1.28e-05 | 778 | 75 | 11 | M17915 |
| Coexpression | LIN_NPAS4_TARGETS_UP | 1.44e-05 | 183 | 75 | 6 | MM767 | |
| Coexpression | SERVITJA_ISLET_HNF1A_TARGETS_UP | 1.53e-05 | 185 | 75 | 6 | MM1072 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_ALVEOLAR_MACROPHAGE_AGEING | 1.58e-05 | 186 | 75 | 6 | MM3762 | |
| Coexpression | ZHANG_UTERUS_C5_MACROPHAGE | 1.63e-05 | 187 | 75 | 6 | MM16611 | |
| Coexpression | TABULA_MURIS_SENIS_SPLEEN_CD8_POSITIVE_ALPHA_BETA_T_CELL_AGEING | 1.63e-05 | 187 | 75 | 6 | MM3833 | |
| Coexpression | ZHANG_UTERUS_C12_MONOCYTE | 1.68e-05 | 188 | 75 | 6 | MM16618 | |
| Coexpression | TABULA_MURIS_SENIS_SPLEEN_CD4_POSITIVE_ALPHA_BETA_T_CELL_AGEING | 1.78e-05 | 190 | 75 | 6 | MM3832 | |
| Coexpression | DURAND_STROMA_NS_UP | 2.00e-05 | 194 | 75 | 6 | MM962 | |
| Coexpression | TABULA_MURIS_SENIS_LIMB_MUSCLE_MESENCHYMAL_STEM_CELL_AGEING | 2.12e-05 | 196 | 75 | 6 | MM3746 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_KIDNEY_PROXIMAL_CONVOLUTED_TUBULE_EPITHELIAL_CELL_AGEING | 2.12e-05 | 196 | 75 | 6 | MM3730 | |
| Coexpression | GSE42021_TREG_PLN_VS_CD24LO_TREG_THYMUS_DN | 2.19e-05 | 197 | 75 | 6 | M9580 | |
| Coexpression | LEE_EARLY_T_LYMPHOCYTE_DN | 2.33e-05 | 58 | 75 | 4 | M13767 | |
| Coexpression | GSE42021_CD24HI_VS_CD24INT_TREG_THYMUS_DN | 2.38e-05 | 200 | 75 | 6 | M9586 | |
| Coexpression | RUAN_RESPONSE_TO_TROGLITAZONE_DN | 2.48e-05 | 20 | 75 | 3 | MM1288 | |
| Coexpression | PHESSE_TARGETS_OF_APC_AND_MBD2_UP | 2.48e-05 | 20 | 75 | 3 | MM890 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_ERYTHROBLAST_AGEING | 2.59e-05 | 203 | 75 | 6 | MM3795 | |
| Coexpression | GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP | 2.89e-05 | 207 | 75 | 6 | MM475 | |
| Coexpression | TABULA_MURIS_SENIS_BROWN_ADIPOSE_TISSUE_B_CELL_AGEING | 3.08e-05 | 311 | 75 | 7 | MM3674 | |
| Coexpression | ZENG_GU_ICB_CONTROL_METAGENE_3_PRECICTIVE_ICB_RESPONSE | 3.21e-05 | 211 | 75 | 6 | MM17081 | |
| Coexpression | TABULA_MURIS_SENIS_MAMMARY_GLAND_BASAL_CELL_AGEING | 3.84e-05 | 322 | 75 | 7 | MM3786 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_AND_AORTA_FIBROBLAST_OF_CARDIAC_TISSUE_AGEING | 4.23e-05 | 327 | 75 | 7 | MM3714 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_PODOCYTE_AGEING | 4.27e-05 | 222 | 75 | 6 | MM3733 | |
| Coexpression | GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN | 4.27e-05 | 222 | 75 | 6 | MM1132 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.69e-06 | 149 | 76 | 5 | 4b44108c40376a6b73258df40d2424e68f991383 | |
| ToppCell | 356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0.5|356C / Donor, Lineage, Cell class and subclass (all cells) | 7.12e-06 | 156 | 76 | 5 | 7ccd20e3bbce6a070df45034b0bdc255f267efb1 | |
| ToppCell | 3'-Adult-Appendix-Epithelial-epithelial_progenitor_cell-Stem_cells|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.31e-05 | 177 | 76 | 5 | 34458f1eb7f3b1fd0cb9904529c01a9ca2f15500 | |
| ToppCell | Multiple_Sclerosis-Lymphocyte-T_NK-gdT|Multiple_Sclerosis / Disease, Lineage and Cell Type | 1.39e-05 | 179 | 76 | 5 | ab8d8104b38603ec7fbc5b35d7149e71ad57c43a | |
| ToppCell | CV-Healthy-7|CV / Virus stimulation, Condition and Cluster | 1.58e-05 | 184 | 76 | 5 | 0e5cc77aaa73ceb791f8be7456177577fd2e5586 | |
| ToppCell | COVID-19_Severe-gd_T|COVID-19_Severe / Disease condition and Cell class | 1.58e-05 | 184 | 76 | 5 | 791f1bcb954aadc63d4117c400537d036f68734d | |
| ToppCell | 5'-Adult-LymphNode-Hematopoietic-T_cells-MAIT_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.62e-05 | 185 | 76 | 5 | 8314dc608bc837df3037e89afd9db39737374ebc | |
| ToppCell | Smart-seq2-bone_marrow_(Smart-seq2)-lymphocytic-innate_lymphocytic|bone_marrow_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.67e-05 | 186 | 76 | 5 | e84a0ba599935ca5e7af48e0fb0500e7ed195d55 | |
| ToppCell | Smart-seq2-bone_marrow_(Smart-seq2)-lymphocytic-innate_lymphocytic-mature_NK_T_cell|bone_marrow_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.67e-05 | 186 | 76 | 5 | 1590fe72badffc79f1d390deb3207116ac2281bb | |
| ToppCell | 5'-GW_trimst-2-SmallIntestine-Hematopoietic-T_cells-Treg|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.67e-05 | 186 | 76 | 5 | 2a9daf96c2a47f1ed5421130f32f17bd33e644a7 | |
| ToppCell | ASK428-Immune-T_cell|ASK428 / Donor, Lineage and Cell class of Lung cells from Dropseq | 1.94e-05 | 192 | 76 | 5 | 121cb8c61002f20e1d287b8a7e67a30bb163e74a | |
| ToppCell | NS-critical-d_0-4-Epithelial-Basal|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.99e-05 | 193 | 76 | 5 | 1affb4c2e21712bde0d36ab736411fe36642cc6d | |
| ToppCell | severe-CD8+_Tem|World / disease stage, cell group and cell class | 2.14e-05 | 196 | 76 | 5 | b8156d31312660fe9c071cb10d7ef22af672c6c8 | |
| ToppCell | Tracheal-10x5prime-Epithelial-Epi_airway_neuro-secretory-Neuroendocrine|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 2.20e-05 | 197 | 76 | 5 | fd76cc5e12c7e7943a48f739e4f0626ff7211f51 | |
| ToppCell | 390C-Lymphocytic-NK_cells|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.25e-05 | 198 | 76 | 5 | 872ddb2738c5e0375830bb0e5b2c50383bf58738 | |
| ToppCell | 390C-Lymphocytic-NK_cells-NK_cell_B|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.25e-05 | 198 | 76 | 5 | 0dc4a564dcab8ac42f238f98ee1f2090b0dcffe6 | |
| ToppCell | Tracheal-10x5prime-Endothelial-Endothelia_vascular-VE_alveolar_capillary_Car4_aerocyte|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 2.25e-05 | 198 | 76 | 5 | c77421898cc84ae2e8cc335087198dd05f13bfa5 | |
| ToppCell | 390C-Lymphocytic|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.30e-05 | 199 | 76 | 5 | d66747762011459ef1d6d311d4a579f245a23be0 | |
| ToppCell | MS-Multiple_Sclerosis-Lymphocyte-T/NK-gd_T|Multiple_Sclerosis / Disease, condition lineage and cell class | 2.36e-05 | 200 | 76 | 5 | 498a2632b111fbf2cd4d755e53698ac5573ba763 | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-SST-CHRNA4-L1|Neuronal / cells hierarchy compared to all cells using T-Statistic | 2.36e-05 | 200 | 76 | 5 | e2ced6eb1de9a526c34c7558b9c637854916e624 | |
| ToppCell | Sepsis-Int-URO-Lymphocyte-T/NK-CD8+_Tem|Int-URO / Disease, condition lineage and cell class | 2.36e-05 | 200 | 76 | 5 | d17a9e3b215490ef9dfc560ff43f190fc688ddc2 | |
| ToppCell | COVID-19-COVID-19_Severe-Lymphocyte-T/NK-gd_T|COVID-19_Severe / Disease, condition lineage and cell class | 2.36e-05 | 200 | 76 | 5 | f72bc3f6606ae77fe1b0a972e35b3ce0727804d9 | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-SST-CHRNA4|Neuronal / cells hierarchy compared to all cells using T-Statistic | 2.36e-05 | 200 | 76 | 5 | 9bc924755e5a4c464408e6103b86bf1b4e8c58b5 | |
| ToppCell | 356C-Myeloid-Macrophage-SPP1+_Macrophage|Macrophage / Donor, Lineage, Cell class and subclass (all cells) | 6.24e-05 | 125 | 76 | 4 | 43aa4b77dccf0ea2979218826af16034f2017c3a | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_3|390C / Donor, Lineage, Cell class and subclass (all cells) | 1.36e-04 | 153 | 76 | 4 | ce7a23c687e9e7d83d244046de19c854caded09b | |
| ToppCell | Brain_organoid-organoid_Velasco_nature|Brain_organoid / Sample Type, Dataset, Time_group, and Cell type. | 1.66e-04 | 161 | 76 | 4 | 2de213169fe1965ceaea545297228117c81d9909 | |
| ToppCell | BL-critical-LOC-Myeloid-Basophil|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.70e-04 | 162 | 76 | 4 | 25ec9df914445b4daae4fd28fd0e60b64797c46d | |
| ToppCell | Multiple_Sclerosis-Lymphocyte-T_NK-CD4_CTL|Multiple_Sclerosis / Disease, Lineage and Cell Type | 1.70e-04 | 162 | 76 | 4 | d53de64df2511eddba79f899fc3f48b1b059923f | |
| ToppCell | 356C-Myeloid-Macrophage-SPP1+_Macrophage|356C / Donor, Lineage, Cell class and subclass (all cells) | 1.70e-04 | 162 | 76 | 4 | 2f19539c455d1e5d514725845234c7547020e6ad | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-Mes-like|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.74e-04 | 163 | 76 | 4 | 360cd65decda24853124f33a174f5224d7f3ce23 | |
| ToppCell | 390C-Lymphocytic-NK_cells-NK_cell_B2|390C / Donor, Lineage, Cell class and subclass (all cells) | 1.74e-04 | 163 | 76 | 4 | 036e65de0f8fc391f3e4d299bf4c05ee5c3b5a37 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-Mes-like-AT1_Progenitor|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.74e-04 | 163 | 76 | 4 | b59d9b4f7c9f4e5e2c7783a49a96729dae3a81e5 | |
| ToppCell | 356C-Lymphocytic-NK_cells-NK_cell_E|356C / Donor, Lineage, Cell class and subclass (all cells) | 1.78e-04 | 164 | 76 | 4 | d5bb57c321f2973836efc8990449494cc1fb87c7 | |
| ToppCell | 356C-Myeloid-Macrophage-SPP1+_Macrophage|Myeloid / Donor, Lineage, Cell class and subclass (all cells) | 1.78e-04 | 164 | 76 | 4 | d6806deabf5f5c355934387be2baae125ac33fb8 | |
| ToppCell | CV-Mild-7|CV / Virus stimulation, Condition and Cluster | 2.04e-04 | 170 | 76 | 4 | 25ebde7d2f8ae1afdfaf5876284ff20bb179eb10 | |
| ToppCell | 390C-Endothelial_cells-Endothelial-C_(Capillary_Aerocyte_)|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 2.04e-04 | 170 | 76 | 4 | a6fa0cab1fa829ec601fe48306b4c43c83425b04 | |
| ToppCell | 390C-Endothelial_cells-Endothelial-C_(Capillary_Aerocyte_)-|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 2.04e-04 | 170 | 76 | 4 | b40255eee45eb18b5a297336d7f3845fd8f8aa3b | |
| ToppCell | metastatic_Brain-T/NK_cells-Cytotoxic_CD8+_T|metastatic_Brain / Location, Cell class and cell subclass | 2.09e-04 | 171 | 76 | 4 | d3e1cc1b70256c4d01488d6b6130bbcae99bdeec | |
| ToppCell | normal_Pleural_Fluid-T/NK_cells-Cytotoxic_CD8+_T|normal_Pleural_Fluid / Location, Cell class and cell subclass | 2.09e-04 | 171 | 76 | 4 | 6be81c20f4e962b414afcedfe478dd59c510d1e1 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.09e-04 | 171 | 76 | 4 | d6d8ea45b443d95f64720c9bc07d324148f5b239 | |
| ToppCell | Nasal_Brush-Epithelial-Basal_1|Nasal_Brush / Tissue, Lineage and Cell class of Lung Cells from 10X | 2.14e-04 | 172 | 76 | 4 | 4483073469001770015526303772fd54906c5d68 | |
| ToppCell | Nasal_Brush-Epithelial-Basal_1|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X | 2.14e-04 | 172 | 76 | 4 | 58eaadf12366701103a0d1f133462c9495fedc30 | |
| ToppCell | CV-Mild-7|Mild / Virus stimulation, Condition and Cluster | 2.18e-04 | 173 | 76 | 4 | c9bbca9313a0fdf146c8c995624b94b937e818d8 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_4|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.18e-04 | 173 | 76 | 4 | b06d6e7acb7086bb99600b680cf404c0ef06b52c | |
| ToppCell | 356C-Lymphocytic-NK_cells-NK_cell_E|NK_cells / Donor, Lineage, Cell class and subclass (all cells) | 2.18e-04 | 173 | 76 | 4 | 090dc3c5bd2652a65c2490fc889da858c3af368f | |
| ToppCell | 5'-Adult-LymphNode-Hematopoietic-T_cells-gdT|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.23e-04 | 174 | 76 | 4 | ccc79febfcf588d8294ffc712338be96de8a5033 | |
| ToppCell | 356C-Lymphocytic-NK_cells-NK_cell_E|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 2.23e-04 | 174 | 76 | 4 | a79ebb01a5849c314e02594a9c95009dbb03cb8c | |
| ToppCell | 356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_6|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 2.28e-04 | 175 | 76 | 4 | f3a68aeb79c4935006e17a5ff3445a8ec0e33f5f | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_Invariant-Inducer-like-MAIT|lymph-node_spleen / Manually curated celltypes from each tissue | 2.33e-04 | 176 | 76 | 4 | 25c197d3b39deffa4801a1d12cdb54320cbae509 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-CD8-positive,_alpha-beta_T_cell-CD8_T_cells-CD8_T_cells_L.1.1.0.4|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.33e-04 | 176 | 76 | 4 | ce85a13e10cf37f5cf38ca8b0bac6701b6d00ffd | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Myeloid-Monocytic-Classical_Monocyte-Mono_c1-CD14-CCL3|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.38e-04 | 177 | 76 | 4 | fd739ae4a574b72dc26a2a9ff4ef988454298ead | |
| ToppCell | IIH-CD8-antiviral_CD4|IIH / Condition, Cell_class and T cell subcluster | 2.38e-04 | 177 | 76 | 4 | fe73608c40701eca88b260aeb5c0640d7bee72ba | |
| ToppCell | CV-Severe-7|Severe / Virus stimulation, Condition and Cluster | 2.38e-04 | 177 | 76 | 4 | 82fdd6185b368f54f03de389427cbe3071d21a99 | |
| ToppCell | Severe-CD4+_T_activated|Severe / Disease group and Cell class | 2.38e-04 | 177 | 76 | 4 | a08f170f1143fcdd7d0842a54d9b807a4548f8b7 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1.5|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.43e-04 | 178 | 76 | 4 | 375c9449be570b4aed83611f9c6fe1665e677818 | |
| ToppCell | 3'-GW_trimst-1-LargeIntestine-Endothelial-lymphatic_endothelial|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.43e-04 | 178 | 76 | 4 | 4ef6344d0ffc9c55b1240bee94b741382f1427bb | |
| ToppCell | 3'-GW_trimst-1-LargeIntestine-Endothelial-lymphatic_endothelial-LEC4_(STAB2+)|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.43e-04 | 178 | 76 | 4 | c65932cbedbbfacb6f0299280663fe7c88dba72b | |
| ToppCell | Severe-CD4+_T_activated|World / Disease group and Cell class | 2.43e-04 | 178 | 76 | 4 | ef6111238703579a34bd6948bd9d4ca6b7e16063 | |
| ToppCell | IIF-Lymphocyte-T_NK-gdT|IIF / Disease, Lineage and Cell Type | 2.43e-04 | 178 | 76 | 4 | 3344d1328fd9c570c3a4b2629edec627a442d0e0 | |
| ToppCell | 3'-Adult-Appendix-Hematopoietic-Plasma_cells-IgA_plasma_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.49e-04 | 179 | 76 | 4 | 2285e3a9018a60d7f6e974fee46b6f61d39aa76f | |
| ToppCell | 3'-Adult-Appendix-Hematopoietic|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.49e-04 | 179 | 76 | 4 | 0b0f27d7c5cc5ae7618d887dcfa7219df8ff1935 | |
| ToppCell | 3'-Adult-Appendix-Hematopoietic-Plasma_cells|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.49e-04 | 179 | 76 | 4 | 63bc819df62b1f8f37bf1f17bdd4fcc161886923 | |
| ToppCell | 5'-GW_trimst-1.5-SmallIntestine-Endothelial-lymphatic_endothelial-LEC2_(MADCAM1+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.49e-04 | 179 | 76 | 4 | dfd5b25f2a6a5a8bf4714f1516cb0997de72b06f | |
| ToppCell | ASK440-Immune-NK_cell|ASK440 / Donor, Lineage and Cell class of Lung cells from Dropseq | 2.54e-04 | 180 | 76 | 4 | 340e750356d23fe9af0e8f298f8a273ff426052f | |
| ToppCell | ASK428-Immune-NK_cell|ASK428 / Donor, Lineage and Cell class of Lung cells from Dropseq | 2.54e-04 | 180 | 76 | 4 | 857d09446e3e6737e83d0f10bfda2ba282d5ba75 | |
| ToppCell | metastatic_Brain-T/NK_cells-CD8_low_T|metastatic_Brain / Location, Cell class and cell subclass | 2.54e-04 | 180 | 76 | 4 | 57eced5e314681857a853f7e6bb8b429f157e80e | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_ADARB2_ADAM33|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.59e-04 | 181 | 76 | 4 | 2f3d04d22d4ac016e61709ea5af3d48885c946c4 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L2-5_VIP_TOX2|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.59e-04 | 181 | 76 | 4 | 35bcdcd2651149692e5b150e887c0f450c81d2d4 | |
| ToppCell | 5'-GW_trimst-1.5-SmallIntestine-Endothelial-lymphatic_endothelial-LEC1_(ACKR4+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.65e-04 | 182 | 76 | 4 | 8d8f28bd43108b2fb3a6c2a3d77a897853d440a4 | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_T_CD8-Trm/em_CD8|lymph-node_spleen / Manually curated celltypes from each tissue | 2.65e-04 | 182 | 76 | 4 | f857b32de19240a8aca1685f7a78b4e53b04875c | |
| ToppCell | 10x3'2.3-week_14-16-Hematopoietic-HSC/MPP_and_pro-LMPP|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 2.65e-04 | 182 | 76 | 4 | 69b5cae6fe3bbb0fc60bd2f71b6cfa6cbb0b00ee | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.70e-04 | 183 | 76 | 4 | 6cdadb3ece45a94a2915063aa461048e1d371ccd | |
| ToppCell | 3'-GW_trimst-1.5-SmallIntestine-Endothelial-lymphatic_endothelial-LEC4_(STAB2+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.70e-04 | 183 | 76 | 4 | a90ffd9c50caa65f537a2e441e37655e1b622327 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Endothelial_Myeloid-Endo|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.70e-04 | 183 | 76 | 4 | c7fc96ac1d5d31ccefe0c1fc6ec76c7d8607a172 | |
| ToppCell | COVID-19_Mild-NK_activated|COVID-19_Mild / Disease condition and Cell class | 2.70e-04 | 183 | 76 | 4 | 22bd05135906d0ecc4ba8c2e0a666093d1bf3b8f | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.70e-04 | 183 | 76 | 4 | e3ffef2b57dc5b96466dccc9cd54ba326ccf378a | |
| ToppCell | 3'-GW_trimst-1.5-SmallIntestine-Endothelial-lymphatic_endothelial|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.70e-04 | 183 | 76 | 4 | 13ad20ec140ef5b96fdace3369b5befc0f40bb76 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial-Endo_L2-5_CLDN5|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.70e-04 | 183 | 76 | 4 | 8714d3e7663c93cdf9b25b647353572e136f30c3 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.76e-04 | 184 | 76 | 4 | 9001d35cdde061d06f8545b3cee942d1299129db | |
| ToppCell | 356C-Lymphocytic-CD8+_Cytotoxic_T-cell|356C / Donor, Lineage, Cell class and subclass (all cells) | 2.76e-04 | 184 | 76 | 4 | 5b4f18b26d03e8e5798cac70d124534749fc4cc0 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial-Endo_L2-5_CLDN5|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.76e-04 | 184 | 76 | 4 | 73eaac74a88bf5fd23d88035fac398ac43b268c5 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Non-neuronal-Endothelial_Myeloid-Endo|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.76e-04 | 184 | 76 | 4 | 65f651d4b93ed0b52f526d3f517d92b6c62aaec3 | |
| ToppCell | CV-Healthy-7|Healthy / Virus stimulation, Condition and Cluster | 2.82e-04 | 185 | 76 | 4 | 1979d189c204f4c2893e3170a514ee7d5523406c | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_ADARB2_ADAM33|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.82e-04 | 185 | 76 | 4 | 487fa382232564f075960899d50afa0edae5d258 | |
| ToppCell | 3'-GW_trimst-1-SmallIntestine-Endothelial-lymphatic_endothelial-LEC4_(STAB2+)|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.82e-04 | 185 | 76 | 4 | fb84fcf7f51f53489bcb3962fa9cb483e48257ed | |
| ToppCell | Somatosensory_Cortex_(S1)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial-Endo_L2-5_CLDN5|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.88e-04 | 186 | 76 | 4 | 422d24e3e1a9397bb7d5c7ef75de2fd7ae8e136d | |
| ToppCell | 3'-GW_trimst-1-SmallIntestine-Endothelial-lymphatic_endothelial|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.88e-04 | 186 | 76 | 4 | 9d250d5ae7cf9129be05b41d70cb6c3a046c5f1e | |
| ToppCell | COVID-19_Severe-CD8+_T_activated|COVID-19_Severe / Disease condition and Cell class | 2.88e-04 | 186 | 76 | 4 | fc087b79240fe7ada5810d4f4b3c7287eab598ff | |
| ToppCell | Somatosensory_Cortex_(S1)-Non-neuronal-Endothelial_Myeloid-Endo|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.88e-04 | 186 | 76 | 4 | 65da0666a10a59f8cc379589860a2e98fe487754 | |
| ToppCell | Somatosensory_Cortex_(S1)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.88e-04 | 186 | 76 | 4 | dc84fef1ca2f5d5d818b76a3321559e87d1c4a4d | |
| ToppCell | tumor_Lung-T/NK_cells-Cytotoxic_CD8+_T|tumor_Lung / Location, Cell class and cell subclass | 2.94e-04 | 187 | 76 | 4 | 530839fb53bb285b22919fde6aa16ce1399615ef | |
| ToppCell | primary_auditory_cortex_(A1C)-Non-neuronal-Endothelial_Myeloid-Endo|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.94e-04 | 187 | 76 | 4 | ed8816433d1086a634892502898255b487a2d4a7 | |
| ToppCell | primary_auditory_cortex_(A1C)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.94e-04 | 187 | 76 | 4 | 698ae9eefa8ba97fea8ea61e4e868edd194de03b | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_ADARB2_ADAM33|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.94e-04 | 187 | 76 | 4 | 02105c82a9ba79d2f19e002188377fc3440770c2 | |
| ToppCell | metastatic_Brain-T/NK_cells-Treg|metastatic_Brain / Location, Cell class and cell subclass | 2.94e-04 | 187 | 76 | 4 | 1b88e1399809c50a0156096d9c82b1d9e58bb720 | |
| ToppCell | primary_auditory_cortex_(A1C)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial-Endo_L2-5_CLDN5|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.94e-04 | 187 | 76 | 4 | d8b09398400a178b03e641af1476c4dac0c6e82a | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_T_CD4/8-lo-Tgd_CRTAM|lymph-node_spleen / Manually curated celltypes from each tissue | 3.06e-04 | 189 | 76 | 4 | e8ff2c4fd2481bfbc99a5a6f02e0db8c995b3a23 | |
| ToppCell | metastatic_Brain-T/NK_cells-CD4+_Th|metastatic_Brain / Location, Cell class and cell subclass | 3.06e-04 | 189 | 76 | 4 | a2b00fbe7b7b15db3fce88a56cbac0ef2917332c | |
| ToppCell | metastatic_Brain-T/NK_cells-NK|metastatic_Brain / Location, Cell class and cell subclass | 3.12e-04 | 190 | 76 | 4 | 50e937ba0600e1ac6215f056bb545dc1e8b28a76 | |
| ToppCell | wk_08-11-Endothelial-Lymph_endothelial-Lymphatic_endo|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 3.12e-04 | 190 | 76 | 4 | 279c5f68b993dc7adbf9aa69fffb1321cdebc48a | |
| Computational | Genes in the cancer module 293. | 2.46e-10 | 12 | 36 | 5 | MODULE_293 | |
| Computational | Genes in the cancer module 143. | 6.18e-10 | 14 | 36 | 5 | MODULE_143 | |
| Computational | Neighborhood of INPP5D | 2.77e-07 | 43 | 36 | 5 | GNF2_INPP5D | |
| Computational | Neighborhood of HLA-C | 4.37e-07 | 47 | 36 | 5 | GNF2_HLA_C | |
| Computational | Neighborhood of PTPN6 | 4.37e-07 | 47 | 36 | 5 | GNF2_PTPN6 | |
| Computational | Neighborhood of CD53 | 1.27e-06 | 58 | 36 | 5 | GNF2_CD53 | |
| Computational | Neighborhood of PTPRC | 2.83e-06 | 68 | 36 | 5 | GNF2_PTPRC | |
| Computational | Neighborhood of CD48 | 3.56e-06 | 32 | 36 | 4 | GNF2_CD48 | |
| Computational | Neighborhood of VAV1 | 5.78e-06 | 36 | 36 | 4 | GNF2_VAV1 | |
| Computational | Neighborhood of STAT6 | 5.95e-06 | 79 | 36 | 5 | GNF2_STAT6 | |
| Computational | Genes upregulated in subsets of cells of a given type within various tumors | 2.19e-05 | 50 | 36 | 4 | GAVISH_3CA_MALIGNANT_METAPROGRAM_17_INTERFERON_MHC_II_1 | |
| Computational | Neighborhood of RAP1B | 2.28e-04 | 36 | 36 | 3 | GNF2_RAP1B | |
| Computational | Neighborhood of CD97 | 2.69e-04 | 38 | 36 | 3 | GNF2_CD97 | |
| Computational | Neighborhood of ICAM3 | 2.90e-04 | 39 | 36 | 3 | GNF2_ICAM3 | |
| Computational | Genes upregulated in subsets of cells of a given type within various tumors | 6.07e-04 | 50 | 36 | 3 | GAVISH_3CA_METAPROGRAM_EPITHELIAL_INTERFERON_MHC | |
| Computational | Neighborhood of ITGA2 | 8.47e-04 | 56 | 36 | 3 | MORF_ITGA2 | |
| Computational | Immune (defense) response. | 1.24e-03 | 142 | 36 | 4 | MODULE_223 | |
| Computational | Genes in the cancer module 493. | 1.55e-03 | 69 | 36 | 3 | MODULE_493 | |
| Drug | ONNO | 5.56e-08 | 12 | 76 | 4 | CID006857661 | |
| Drug | tert-butyl acetate | 1.45e-06 | 58 | 76 | 5 | CID000010908 | |
| Drug | vinylene | 1.61e-06 | 245 | 76 | 8 | CID000006326 | |
| Drug | BMS-186282 | 1.66e-05 | 95 | 76 | 5 | CID000002416 | |
| Drug | Cefadroxil | 3.29e-05 | 3 | 76 | 2 | ctd:D002434 | |
| Disease | graft-versus-host disease (implicated_via_orthology) | 1.08e-12 | 7 | 67 | 5 | DOID:0081267 (implicated_via_orthology) | |
| Disease | Parapsoriasis en Plaques | 5.08e-06 | 2 | 67 | 2 | C0162442 | |
| Disease | – | 5.08e-06 | 2 | 67 | 2 | 608579 | |
| Disease | Susceptibility to severe cutaneous adverse reaction | 5.08e-06 | 2 | 67 | 2 | cv:C1840548 | |
| Disease | Erythroderma, Maculopapular | 5.08e-06 | 2 | 67 | 2 | C0014799 | |
| Disease | Carbamazepine response | 5.08e-06 | 2 | 67 | 2 | cv:CN077964 | |
| Disease | Parakeratosis Variegata | 5.08e-06 | 2 | 67 | 2 | C0030437 | |
| Disease | Parapsoriasis | 5.08e-06 | 2 | 67 | 2 | C0030491 | |
| Disease | occupational asthma (is_implicated_in) | 3.04e-05 | 4 | 67 | 2 | DOID:0080820 (is_implicated_in) | |
| Disease | Stevens-Johnson syndrome (is_implicated_in) | 3.04e-05 | 4 | 67 | 2 | DOID:0050426 (is_implicated_in) | |
| Disease | cytokine measurement | 8.41e-05 | 461 | 67 | 7 | EFO_0004873 | |
| Disease | beta-2 microglobulin measurement | 2.76e-04 | 11 | 67 | 2 | EFO_0005197 | |
| Disease | unipolar depression, multiple sclerosis | 3.30e-04 | 12 | 67 | 2 | EFO_0003761, MONDO_0005301 | |
| Disease | susceptibility to cold sores measurement | 4.42e-04 | 65 | 67 | 3 | EFO_0008402 | |
| Disease | apolipoprotein B measurement | 7.58e-04 | 663 | 67 | 7 | EFO_0004615 | |
| Disease | basophil count | 8.00e-04 | 483 | 67 | 6 | EFO_0005090 | |
| Disease | susceptibility to shingles measurement | 8.41e-04 | 81 | 67 | 3 | EFO_0008401 | |
| Disease | autism spectrum disorder, schizophrenia | 8.92e-04 | 327 | 67 | 5 | EFO_0003756, MONDO_0005090 | |
| Disease | susceptibility to Mycobacterium tuberculosis infection measurement | 1.00e-03 | 86 | 67 | 3 | EFO_0008407 | |
| Disease | osteoarthritis | 1.65e-03 | 222 | 67 | 4 | MONDO_0005178 | |
| Disease | cholesteryl ester measurement, very low density lipoprotein cholesterol measurement | 1.73e-03 | 225 | 67 | 4 | EFO_0008317, EFO_0010351 | |
| Disease | tuberculosis (is_implicated_in) | 1.85e-03 | 28 | 67 | 2 | DOID:399 (is_implicated_in) | |
| Disease | Oral ulcer | 1.88e-03 | 107 | 67 | 3 | HP_0000155 | |
| Disease | Drug-Induced Stevens Johnson Syndrome | 1.98e-03 | 29 | 67 | 2 | C1274933 | |
| Disease | Toxic Epidermal Necrolysis | 1.98e-03 | 29 | 67 | 2 | C0014518 | |
| Disease | Mycoplasma-Induced Stevens-Johnson Syndrome | 1.98e-03 | 29 | 67 | 2 | C3658301 | |
| Disease | Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum | 1.98e-03 | 29 | 67 | 2 | C3658302 | |
| Disease | Stevens-Johnson Syndrome | 2.12e-03 | 30 | 67 | 2 | C0038325 | |
| Disease | tonsillectomy risk measurement | 2.92e-03 | 260 | 67 | 4 | EFO_0007924 | |
| Disease | cholesteryl ester measurement, low density lipoprotein cholesterol measurement | 2.98e-03 | 126 | 67 | 3 | EFO_0004611, EFO_0010351 | |
| Disease | mosquito bite reaction itch intensity measurement | 3.19e-03 | 129 | 67 | 3 | EFO_0008377 | |
| Disease | Stevens-Johnson syndrome, toxic epidermal necrolysis, response to cold medicine | 3.21e-03 | 37 | 67 | 2 | EFO_0004276, EFO_0004775, EFO_0006997 | |
| Disease | allergic rhinitis | 3.47e-03 | 133 | 67 | 3 | EFO_0005854 | |
| Disease | free cholesterol measurement, low density lipoprotein cholesterol measurement | 3.78e-03 | 137 | 67 | 3 | EFO_0004611, EFO_0008591 | |
| Disease | spleen volume | 4.32e-03 | 43 | 67 | 2 | EFO_0600047 | |
| Disease | cholesterol:total lipids ratio, low density lipoprotein cholesterol measurement | 4.34e-03 | 144 | 67 | 3 | EFO_0004611, EFO_0020943 | |
| Disease | visceral:gluteofemoral adipose tissue ratio measurement | 4.72e-03 | 45 | 67 | 2 | EFO_0803319 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| HQRIHVGERPYECNE | 316 | Q9HBT8 | |
| HVQPRTIYLCRHGES | 246 | O60825 | |
| YHELQGEIHCGTNVR | 636 | Q9ULC6 | |
| PPGEEQRYTCHVQHE | 271 | P30511 | |
| GEEQRYTCHVQHEGL | 276 | P01893 | |
| GEEQRYTCHVQHEGL | 276 | P17693 | |
| PSGEEQRYTCHVQHE | 271 | P13747 | |
| PHQFIHRICDEITGR | 96 | Q8N335 | |
| NIHVQPRTIYLCRHG | 241 | Q16875 | |
| PRTIYLCRHGENEHN | 246 | Q16875 | |
| CRSRVEHVQHVYLPT | 421 | Q8WY64 | |
| GEEQRYTCHVQHEGL | 276 | P01889 | |
| QGDVIRHYGEHVCTA | 326 | Q9BQG0 | |
| EVCYTVINHIPHQRS | 66 | Q5JQS6 | |
| DGHPNVLHDCQRYRS | 96 | O75146 | |
| AYANPTVVRCEIHHG | 486 | Q86XK2 | |
| RPEGRVNVYHHLVET | 311 | P36269 | |
| GEEQRYTCHVQHEGL | 276 | P04439 | |
| PHCFSHQNGERVERY | 456 | Q17RY0 | |
| IHHPSSRIIEYCRND | 291 | Q8IWZ5 | |
| RVGTTVHCDYLNIPH | 1376 | Q8IZX4 | |
| QAQILHCYRDRPHEV | 201 | Q9BRQ6 | |
| NLGCDVHQTEHVYRV | 306 | Q9Y227 | |
| PHSEHQGVVYCRAEA | 236 | Q15198 | |
| YICHNRTVIHHRVPN | 146 | P36897 | |
| NYILPHLRGEDRVCH | 36 | Q5SV17 | |
| HQRIHTGERPYECNE | 286 | Q6P2D0 | |
| LRHQKVHTQVRPYEC | 391 | P52740 | |
| HQRIHSGDLPYVCNE | 436 | P13682 | |
| VIEHQRIHTGERPYE | 191 | O75820 | |
| RHQRIHTGERPYQCN | 221 | O75820 | |
| CTQHQRLHTGQRPYE | 716 | Q8NHY6 | |
| RHQEVHTGARPYVCS | 386 | Q8TAW3 | |
| HQRCHTEQRPYRCGV | 866 | P0CJ78 | |
| VHERSHTGDRPYQCE | 256 | P52747 | |
| CTYLQIHERIHTGER | 431 | Q8N8Z8 | |
| VHQRIHTGENPYECS | 741 | Q14587 | |
| IQPCHIREAIRRYSH | 281 | O75486 | |
| RHQRIHTGERPYQCE | 206 | P17023 | |
| HQRVHTGERPYMCDV | 401 | A6NJL1 | |
| HQRVHTGQTAYPCEE | 286 | Q96SQ5 | |
| CFINHQRVHTGERPY | 366 | Q96SQ5 | |
| HQRLHTGERPYNCRE | 426 | Q96SQ5 | |
| IHQRIHTGERPYECS | 481 | Q96SQ5 | |
| TNHQRIHSGERPYEC | 591 | Q9Y2P7 | |
| IQHQVVHTGERPYEC | 451 | Q3SY52 | |
| CFINHQRVHTGERPY | 366 | Q8TAU3 | |
| VQHQRGHTGERPYEC | 396 | Q8TAU3 | |
| HQRLHTGERPYNCRE | 426 | Q8TAU3 | |
| IHQRIHTGERPYECN | 481 | Q8TAU3 | |
| IEHQRVHTGERPYEC | 351 | Q7Z340 | |
| QHQRIHSGERPYECR | 436 | Q7Z340 | |
| IQHQRVHTGERPYEC | 491 | Q7Z340 | |
| QHQRVHTGERPYECS | 576 | Q7Z340 | |
| IQHQRVHTGERPYEC | 631 | Q7Z340 | |
| IIHQRVHTGERPYAC | 301 | Q13398 | |
| YHQRVHTGERPHECN | 386 | Q13398 | |
| HHEACVRLRPQTYDL | 76 | Q92599 | |
| YNCPPTHENVHIRRE | 1856 | Q68DE3 | |
| IVHVRTHSAGRPYQC | 606 | Q96JL9 | |
| VQHHRIHTGVRPYEC | 291 | Q6PK81 | |
| DMHQRVHTGERPYNC | 556 | Q9UK10 | |
| HQSVHSGERPYICEV | 711 | Q9UJU3 | |
| EFHQRVHTGERPYNC | 466 | Q9UK13 | |
| RHQRTHTGERPYECN | 201 | Q8IVP9 | |
| QHQRVHTGERPYECS | 341 | Q8IVP9 | |
| AQHQRIHTGERPYEC | 486 | Q96NI8 | |
| LVQHQRVHTGERPYE | 301 | Q8TF45 | |
| EHQRVHTGERPYECN | 471 | Q8TF45 | |
| HQRIHSGEEPYQCNE | 471 | Q8NF99 | |
| QHQRIHSRERPYECS | 271 | Q3KQV3 | |
| HQRVHTGERPYECSE | 411 | Q8NEK5 | |
| QTHQRVHTGEKPYRC | 536 | Q86WZ6 | |
| QHRRLHTGERPYQCS | 296 | Q5T619 | |
| QHIRMHNGERPYQCE | 521 | Q5T619 | |
| IQHQRVHTGERPYEC | 311 | Q6P9A1 | |
| VLIQHQRVHTGERPY | 421 | Q6P9A1 | |
| HQTVHTGERPYECSV | 481 | Q6P9A1 | |
| DQGHYVCRVQEISRH | 121 | Q8IW00 | |
| VQHQRIHTGERPYKC | 351 | Q9HCX3 | |
| THQRIHVGERPYECN | 316 | P0CG31 | |
| RHQRIHTGERPYECN | 271 | O15535 | |
| IQHQLIHTGERPYEC | 386 | Q14585 | |
| IRHQRIHTGERPYEC | 251 | O75123 | |
| QHQRIHTGERPYVCN | 336 | O75123 | |
| HQRVHTGERPYICDV | 701 | Q14590 | |
| LVQHQRVHTGERPYE | 281 | Q68DY9 | |
| VQHESIHTGERPYEC | 366 | Q68DY9 | |
| RQRYPANCTVRDHVH | 151 | Q9BRN9 | |
| LHQRIHTGERPYQCA | 566 | Q96RE9 | |
| QHQRIHTGERPYECS | 221 | P52741 | |
| HQRIHTGERPYECSE | 516 | P17021 | |
| HQRIHTGERPYVCSE | 661 | Q9Y473 | |
| RHQVIHTGSQPYQCV | 386 | Q5FWF6 | |
| VQHQRIHTGEKPYRC | 326 | Q8TF47 | |
| EHQRVHTGERPYECG | 281 | Q68DI1 | |
| VHHQRVHTGERPYQC | 336 | Q68DI1 | |
| EHQRVHTGERPYECR | 421 | Q68DI1 |